Pharmacotherapies Targeting GABA-Glutamate Neurotransmission for Treatment-Resistant Depression
Open accessThe DOI matches its Crossref record; 177 of the 179 references it cites were found in a registry or an index; 83 of the 280 sources its claims cite were checked for support.
Abstract
Treatment-resistant depression (TRD) is a term used to describe a particular type of major depressive disorder (MDD). There is no consensus about what defines TRD, with various studies describing between 1 and 4 failures of antidepressant therapies, with or without electroconvulsive therapy (ECT). That is why TRD is such a growing concern among clinicians and researchers, and it explains the necessity for investigating novel therapeutic targets beyond conventional monoamine pathways. An imbalance between two primary central nervous system (CNS) neurotransmitters, L-glutamate and γ-aminobutyric acid (GABA), has emerged as having a key role in the pathophysiology of TRD. In this review, we provide an evaluation and comprehensive review of investigational antidepressants targeting these two systems, accessing their levels of available evidence, mechanisms of action, and safety profiles. N-methyl-D-aspartate (NMDA) receptor antagonism has shown the most promise amongst the glutamatergic targets, with ketamine and esketamine (Spravato) robustly generating responses across trials. Two specific NMDA-glycine site modulators, D-cycloserine (DCS) and apimostinel, have also generated promising initial safety and efficacy profiles, warranting further investigation. Combination dextromethorphan-bupropion (AXS-05/Auvelity) displays a unique mechanism of action and demonstrated positive results in particular applicability in subpopulations with cognitive dysfunction. Currently, the most promising GABA modulators appear to be synthetic neurosteroid analogs with positive GABAA receptor modulation (such as brexanolone). Overall, advances in the last decade provide exciting perspectives for those who do not improve with conventional therapies. Of the compounds reviewed here, three are approved by the Food and Drug Administration (FDA): esketamine (Spravato) for TRD, Auvelity (dextromethorphan-bupropion) for major depressive disorder (MDD), and brexanolone (Zulresso) for post-partum depression (PPD). Notably, some concerns have arisen with esketamine and brexanolone, which will be detailed in this study.
Overview
CoChat Summary
TL;DR
This review evaluates investigational pharmacotherapies targeting glutamate–GABA neurotransmission for treatment-resistant depression (TRD), concluding that NMDA receptor antagonism—especially ketamine and esketamine—has the strongest evidence, while synthetic neurosteroid GABA-A modulators are the most promising GABAergic agents. Three reviewed compounds are FDA-approved: esketamine for TRD, dextromethorphan–bupropion (Auvelity) for MDD, and brexanolone for postpartum depression.
Key findings
- TRD lacks a consensus definition; the modal definition is lack of response or remission after two adequate antidepressant trials, but only 17% of studies implement these criteria, and approximately one-third of depressed patients fail to remit even after four adequate therapeutic trials.
- Ketamine has robust evidence: a single dose can alleviate depressive symptoms for up to seven days with effects peaking at 24 h, and repeated infusions maintain effects for two to three weeks in MDD; a meta-analysis favored intravenous ketamine over intranasal esketamine for response (RR = 3.01 vs. 1.38), remission (RR = 3.70 vs. 1.47), and lower dropouts (RR = 0.76 vs. 1.37).
- Esketamine nasal spray was approved in 2019 for TRD after five phase III randomized double-blind placebo-controlled trials and one open-label trial; a long-term open-label study reported sustained improvement at 2 years, with 0.6% discontinuing for worsening depression and 0.2% for suicidal ideation, though one successful suicide occurred.
- Among GABA modulators, brexanolone is FDA-approved for postpartum depression, and zuranolone showed significant clinical improvements at day 3 and day 42 in MDD and at days 3, 15, 28, and 45 in 196 patients with postpartum depression; zuranolone was subsequently FDA-approved for postpartum depression.
Methods
- Narrative review of clinical studies up to September 2023 of investigational compounds targeting glutamatergic and/or GABAergic systems as their primary antidepressant mechanism, including compounds with evidence of antidepressant efficacy in at least one successful clinical trial.
- Evidence levels for antidepressant efficacy are summarized in Tables 1–3; psychedelics ayahuasca and psilocybin are mentioned but not formally included because their direct glutamate/GABA modulation in relation to antidepressant efficacy is unclear.
- The paper does not report a systematic search strategy, databases, inclusion/exclusion criteria, or quantitative synthesis; this is evident from the Methods section.
Limitations
- Stated: no clear consensus definition of TRD, with only 17% of studies using the modal two-adequate-trial definition.
- Stated across trials: inability to effectively blind subjects and raters to ketamine/esketamine, homogenous samples, short durations, limited real-world feasibility, high dropout in some esketamine trials, and safety concerns including suicidality and REMS restrictions for esketamine and brexanolone.
- Evident from the text: as a narrative review, it lacks a systematic search and meta-analytic synthesis; many compounds have small samples, short durations, and virtually identical designs, requiring larger and longer randomized controlled trials.
Model-written summary. Check it against the paper before relying on it.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
36 Valid · 8 Not valid · 132 Not checked · 20 Own results and interpretations
At least one cited source doesn’t support this claim or points to a different paper, and none confirmed it — see the verdicts below.
In the paper
“Fedgchin’s group conducted an analogous study, which did not support adjunctive esketamine’s AD efficacy for TRD [111].”
§ Pharmacotherapies Targeting GABA-Glutamate Neurotransmission for Treatment-Resistant Depression > 4. Clinical Studies with Glutamate Modulators in TRD > 4.1. Ketamine and Similar Compounds
What the sources say
- Disputedcites [111] Fedgchin, 2019, Efficacy and Safety of Fixed-Dose Esketamine Nasal Spray Combined with a New Oral Antidepressant in Treatment-Resistant Depression: Results of a Randomized, Double-Blind, Active-Controlled Study (TRANSFORM-1), Int. J. Neuropsychopharmacol. sourceExperimental — accuracy not yet measured
Our copy confirms the factual kernel — TRANSFORM-1's primary endpoint was not met (esketamine 84 mg/antidepressant vs antidepressant/placebo: LS mean difference -3.2 [-6.88, 0.45], 2-sided P = .088; Abstract Results and Study Results) — but the paper draws the opposite conclusion from the claim: both the Abstract Conclusions and the Discussion summary state that the study 'provides supportive evidence for the safety and efficacy of esketamine nasal spray' in TRD, noting treatment effects for both esketamine doses (-3.2 and -4.1) exceeded the ~2-point difference considered clinically meaningful, nominal P = .027 for 56 mg, and numerically favorable key secondary and subgroup results (Discussion, Table 4 post hoc pooled-dose difference -3.8, 95% CI -6.92 to -0.70). Saying the study 'did not support' adjunctive esketamine's antidepressant efficacy therefore contradicts what the source itself asserts; the Discussion only attributes the lack of statistical significance to methodological factors (3-fold higher withdrawal in the 84 mg arm, unexpected antidepressant/placebo improvement, 1/3 placebo randomization). (LLM, conf=0.72)
Checked by a reasoning model — may be wrong.
plain- Asserted: passes — The authors put it forward as true.
- Checkable: passes — It can be checked against evidence.
- Load-bearing: unclear — It is unclear whether the paper’s conclusions depend on it.
- Based: passes — The paper gives a reason why it holds.
- Disputed
At least one cited source doesn’t support this claim or points to a different paper, and none confirmed it — see the verdicts below.
In the paper
“Due to its short half-life, DM lacks AD efficacy as a monotherapy, but in conjunction with quinidine, a CYP2D6 enzyme inhibitor that limits DM metabolism, it produces more lasting AD effects [148,149].”
§ Pharmacotherapies Targeting GABA-Glutamate Neurotransmission for Treatment-Resistant Depression > 4. Clinical Studies with Glutamate Modulators in TRD > 4.2. Dextromethorphan and Similar Compounds
What the sources say
- Disputedcites [148] Nguyen, L., Robson, M.J., Healy, J.R., Scandinaro, A.L., and Matsumoto, R.R. (2014). Involvement of Sigma-1 Receptors in the Antidepressant-like Effects of Dextromethorphan. PLoS ONE, 9. sourceExperimental — accuracy not yet measured
The Results (Effects of CYP2D6 Inhibitor Quinidine on Dextromethorphan Dose Response; page unavailable) report that dextromethorphan alone at 30 mg/kg produced a significant antidepressant-like effect in mice. The 10 mg/kg dose was not significant alone, and quinidine potentiated its effect, but those findings do not support the categorical claim that dextromethorphan lacks efficacy as a monotherapy due to a short half-life. The study does not establish clinical efficacy in humans. (LLM, conf=0.86)
Checked by a reasoning model — may be wrong.
- Not checked yetcites [149] Nguyen, 2015, Involvement of AMPA receptors in the antidepressant-like effects of dextromethorphan in mice, Behav. Brain Res. source
plainstates a cause- Asserted: passes — The authors put it forward as true.
- Checkable: passes — It can be checked against evidence.
- Load-bearing: unclear — It is unclear whether the paper’s conclusions depend on it.
- Based: passes — The paper gives a reason why it holds.
- Disputed
The cited sources support only part of this claim — read each source’s verdict below.
In the paper
“An imbalance between two primary central nervous system (CNS) neurotransmitters, L-glutamate and γ-aminobutyric acid (GABA), has emerged as having a key role in the pathophysiology of TRD.”
- Also stated in: § 2. Glutamate and GABA Dysfunction in Depression · boosted
“Glutamatergic and GABAergic dysfunction in the prefrontal cortex (PFC) and anterior cingulate cortex (ACC) has been extensively implicated in both MDD and TRD [16,17,18,19,20,21,22,23,24,25].”
§ Pharmacotherapies Targeting GABA-Glutamate Neurotransmission for Treatment-Resistant Depression > Abstract
What the sources say
- Not checked yetcites [16] Abdallah, 2017, Prefrontal Connectivity and Glutamate Transmission: Relevance to Depression Pathophysiology and Ketamine Treatment, Biol. Psychiatry Cogn. Neurosci. Neuroimaging
- Not checked yetcites [17] Berman, 2011, Depression, rumination and the default network, Soc. Cogn. Affect. Neurosci. source
- Not checked yetcites [18] Buckner, 2008, The Brain’s Default Network: Anatomy, Function, and Relevance to Disease, Ann. N. Y. Acad. Sci. source
- Partly supportedcites [19] Gabbay, 2012, Anterior Cingulate Cortexγ-Aminobutyric Acid in Depressed Adolescents: Relationship to Anhedonia, Arch. Gen. Psychiatry sourceExperimental — accuracy not yet measured
The introduction links dysregulation of GABA and glutamate to anhedonia and MDD pathophysiology, and the Comment says the two systems may be linked. The study concerns adolescents with MDD, not treatment-resistant depression (TRD), and does not establish that an imbalance between the neurotransmitters has a key role in TRD. (LLM, conf=0.86)
- Not checked yetcites [20] Horn, 2010, Glutamatergic and resting state functional connectivity correlates of severity in major depression—The role of pregenual anterior cingulate cortex and anterior insula, Front. Syst. Neurosci.
- Partly supportedcites [21] Isaacson, 2011, How Inhibition Shapes Cortical Activity, Neuron sourceExperimental — accuracy not yet measured
In “Inhibition’s impact on membrane potential and excitability” (page unavailable), the paper identifies glutamate with cortical excitation and GABA with inhibition. In “The ‘balance’ of excitation and inhibition” (page unavailable), it says disrupting their relationship can impair cortical activity. It does not connect that imbalance to treatment-resistant depression or establish a key role in its pathophysiology. (LLM, conf=0.83)
- Could not verifycites [22] Pizzagalli, 2018, Pretreatment Rostral Anterior Cingulate Cortex Theta Activity in Relation to Symptom Improvement in Depression: A Randomized Clinical Trial, JAMA Psychiatry sourceExperimental — accuracy not yet measured
The Discussion mentions possible glutamatergic abnormalities underlying altered rACC activity, but does not discuss an imbalance between glutamate and GABA. Searches for GABA and neurotransmitter imbalance found no passage linking that imbalance to treatment-resistant depression; the Limitations section says it is unclear whether the study's findings generalize to treatment-resistant samples. (LLM, conf=0.74)
- Partly supportedcites [23] Price, 2009, Amino Acid Neurotransmitters Assessed by Proton Magnetic Resonance Spectroscopy: Relationship to Treatment Resistance in Major Depressive Disorder, Biol. Psychiatry sourceExperimental — accuracy not yet measured
The Results report an elevated occipital glutamate-plus-glutamine-to-GABA (Glx:GABA) ratio in TRD, and the Discussion describes the findings as consistent with amino acid neurotransmitter dysfunction. But the Discussion says the study cannot establish cause and effect; it does not establish that an L-glutamate–GABA imbalance has a key role in TRD pathophysiology. Page numbers are unavailable in our copy. (LLM, conf=0.88)
- Partly supportedcites [24] Walton, N., and Maguire, J. (2019). Allopregnanolone-based treatments for postpartum depression: Why/how do they work?. Neurobiol. Stress, 11. sourceExperimental — accuracy not yet measured
The section “Diverse etiology of postpartum depression with relevance to allopregnanolone” says GABAergic deficits could contribute to depression and discusses a GABAergic hypothesis for major depressive disorder. It does not establish a glutamate–GABA imbalance as a key mechanism in treatment-resistant depression (TRD); the glutamate search found it only in a reference title. No page number was provided for these passages. (LLM, conf=0.86)
- Could not verifycites [25] Zhou, 2020, Rumination and the default mode network: Meta-analysis of brain imaging studies and implications for depression, NeuroImage sourceExperimental — accuracy not yet measured
The paper’s Abstract and Section 4.3 discuss default-mode-network activity during rumination and implications for depression, not a glutamate–GABA imbalance in treatment-resistant depression. Searches for L-glutamate, GABA, and treatment-resistant depression found no passage in our copy addressing the claimed mechanism. (LLM, conf=0.75)
boostedstates a cause- Asserted: passes — The authors put it forward as true.
- Checkable: passes — It can be checked against evidence.
- Load-bearing: passes — The paper’s conclusions depend on it.
- Based: passes — The paper gives a reason why it holds.
- Also stated in: § 2. Glutamate and GABA Dysfunction in Depression · boosted
The cited sources support only part of this claim — read each source’s verdict below.
In the paper
“Specifically, cortical GABAergic disinhibition in depressive disorders co-occurs with increases in glutamatergic gene expression in the DMN [24,26,27,28,29,30,31,32].”
§ Pharmacotherapies Targeting GABA-Glutamate Neurotransmission for Treatment-Resistant Depression > 2. Glutamate and GABA Dysfunction in Depression
What the sources say
- Partly supportedcites [24] Walton, N., and Maguire, J. (2019). Allopregnanolone-based treatments for postpartum depression: Why/how do they work?. Neurobiol. Stress, 11. sourceExperimental — accuracy not yet measured
In “Diverse etiology of postpartum depression with relevance to allopregnanolone” (page not available), the review discusses GABAergic deficits in depression and reports a correlation between GABA levels and default mode network connectivity in women with postpartum depression. It does not report increased glutamatergic gene expression in the DMN or establish that such an increase co-occurs with cortical GABAergic disinhibition. (LLM, conf=0.84)
- Partly supportedcites [26] Deligiannidis, 2019, Resting-state functional connectivity, cortical GABA, and neuroactive steroids in peripartum and peripartum depressed women: A functional magnetic resonance imaging and spectroscopy study, Neuropsychopharmacology sourceExperimental — accuracy not yet measured
The Discussion (p. 7) notes that major depressive disorder has been associated with reduced cortical GABA, while reporting no between-group GABA difference in this study. The paper reports altered DMN connectivity in postpartum depression (p. 1), but it does not report increased glutamatergic gene expression in the DMN or its co-occurrence with GABAergic disinhibition. (LLM, conf=0.86)
- Not checked yetcites [27] Gray, 2015, Sex differences in glutamate receptor gene expression in major depression and suicide, Mol. Psychiatry source
- Not checked yetcites [28] Levinson, 2010, Evidence of Cortical Inhibitory Deficits in Major Depressive Disorder, Biol. Psychiatry source
- Not checked yetcites [29] Papp, 1994, Antidepressant activity of non-competitive and competitive NMDA receptor antagonists in a chronic mild stress model of depression, Eur. J. Pharmacol. source
- Partly supportedcites [30] Seney, 2018, Opposite Molecular Signatures of Depression in Men and Women, Biol. Psychiatry sourceExperimental — accuracy not yet measured
The Introduction (page not available) reports reduced expression of the GABA-neuron marker somatostatin and increased expression of glutamate-related genes in women with major depressive disorder; it reports decreased expression of those glutamate-related genes in men. The paper does not establish GABAergic disinhibition co-occurring with glutamatergic increases in the default mode network, and its findings are sex-specific rather than a general pattern across depressive disorders. (LLM, conf=0.86)
- Partly supportedcites [31] Tripp, 2011, Reduced somatostatin in subgenual anterior cingulate cortex in major depression, Neurobiol. Dis. sourceExperimental — accuracy not yet measured
The Introduction (page unavailable) describes evidence of impaired excitation–inhibition balance and reduced cortical GABA in major depression. The Discussion (page unavailable) reports reduced somatostatin, an inhibitory peptide, in the subgenual anterior cingulate cortex. The paper does not report co-occurring increases in glutamatergic gene expression or establish that pattern across the default mode network. (LLM, conf=0.86)
- Partly supportedcites [32] Zhao, 2018, Prefrontal alterations in GABAergic and glutamatergic gene expression in relation to depression and suicide, J. Psychiatr. Res. sourceExperimental — accuracy not yet measured
The Results (section 3.3, p. 6) report increased glutamatergic gene expression in the DLPFC of patients with MDD and in the ACC of patients with MDD who died by suicide. They also report increases in GABAergic markers in those groups, rather than demonstrating cortical GABAergic disinhibition. The paper examines these prefrontal regions, not gene expression across the default mode network. (LLM, conf=0.88)
plainstates an association- Asserted: passes — The authors put it forward as true.
- Checkable: passes — It can be checked against evidence.
- Load-bearing: unclear — It is unclear whether the paper’s conclusions depend on it.
- Based: passes — The paper gives a reason why it holds.
- Partly supported
The cited sources support only part of this claim — read each source’s verdict below.
In the paper
“Diminishing returns demonstrated in the Sequenced Treatment Alternatives to Relieve Depression (STAR*D) trial underscore the need for novel treatment avenues targeting the pathophysiological source of treatment resistance [4].”
§ Pharmacotherapies Targeting GABA-Glutamate Neurotransmission for Treatment-Resistant Depression > 1. Introduction: The Problem of TRD
What the sources say
- Partly supportedcites [4] Trivedi, 2006, Medication Augmentation after the Failure of SSRIs for Depression, N. Engl. J. Med. sourceExperimental — accuracy not yet measured
The introduction (page unavailable) identifies this as a STAR*D second-step study for patients who did not remit with citalopram, and Symptom Outcomes reports remission rates of about 30% with either augmentation drug. The paper does not compare remission across successive treatment steps to demonstrate diminishing returns, nor does it call for novel treatments targeting the pathophysiology of resistance. (LLM, conf=0.82)
boostedstates a cause- Asserted: passes — The authors put it forward as true.
- Checkable: passes — It can be checked against evidence.
- Load-bearing: passes — The paper’s conclusions depend on it.
- Based: passes — The paper gives a reason why it holds.
- Partly supported
79 more claims · 21 with their cited sources checked
Create a free account to see all 196 claims and to verify the 197 references still open.
- It may state two separate claims as one. 100
- Probably not a substantial claim. 25
- The quote only partly states this claim. 1
Claims other papers make about this one
Each is checked against this paper’s own text: does it say what the citing paper says it does?
The source backs part of the claim, not all of it — or backs it for a different population, condition or comparison.
In the citing paper
“Common adverse effects include dissociation, dizziness, and blood pressure (BP) elevation [52,53,55].”
From Synaptic Plasticity—Intrinsic Excitability and Antidepressant Discovery (2026) · cites this paper as [53]
Experimental — accuracy not yet measuredThe source backs part of the claim, not all of it — or backs it for a different population, condition or comparison.
In the citing paper
“Clinically, esketamine nasal spray demonstrates rapid efficacy in treatment-resistant depression (TRD), with improvements emerging within hours to days and sustained by maintenance dosing [53].”
From Synaptic Plasticity—Intrinsic Excitability and Antidepressant Discovery (2026) · cites this paper as [53]
Experimental — accuracy not yet measured
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
Each contradiction between two passages listed here was confirmed by an independent check.
Rated major: it would touch a result — a value a result rests on, reported and recomputed p-values on opposite sides of the significance level, two passages that conflict with no sign which is right, or a cited work retracted before this paper was published.
In the paper
§ Pharmacotherapies Targeting GABA-Glutamate Neurotransmission for Treatment-Resistant Depression > Abstract
“Of the compounds reviewed here, three are approved by the Food and Drug Administration (FDA): esketamine (Spravato) for TRD, Auvelity (dextromethorphan-bupropion) for major depressive disorder (MDD), and brexanolone (Zulresso) for post-partum depression (PPD).”
§ Pharmacotherapies Targeting GABA-Glutamate Neurotransmission for Treatment-Resistant Depression > 6. Conclusions
“Of the compounds reviewed here, two are FDA-approved: esketamine (Spravato) for TRD and BRX (Zulresso) for PPD.”
Rated minor: it would not touch a result — a value no result rests on, a p-value that stays on the same side of the significance level, or a conflict that is clerical, resolved elsewhere in the paper, or outside its own findings.
In the paper
§ Pharmacotherapies Targeting GABA-Glutamate Neurotransmission for Treatment-Resistant Depression > 6. Conclusions
“N2O was discontinued from development due to side effects and abuse potential.”
§ Pharmacotherapies Targeting GABA-Glutamate Neurotransmission for Treatment-Resistant Depression > 4. Clinical Studies with Glutamate Modulators in TRD > 4.1. Ketamine and Similar Compounds
“Several trials with N2O are currently enrolling for depression (MDD and bipolar), suicidal ideation, post-traumatic stress disorder, and others [129].”
Rated minor: it would not touch a result — a value no result rests on, a p-value that stays on the same side of the significance level, or a conflict that is clerical, resolved elsewhere in the paper, or outside its own findings.
In the paper
§ Pharmacotherapies Targeting GABA-Glutamate Neurotransmission for Treatment-Resistant Depression > 6. Conclusions
“Zuranolone is scheduled to receive a response from FDA in August 2023 about the approval or not since the application has been granted priority by the agency [193].”
§ Pharmacotherapies Targeting GABA-Glutamate Neurotransmission for Treatment-Resistant Depression > 5. Clinical Studies with GABA Modulation in TRD > GABAA Receptor Positive Modulation
“Due to those very recent findings, Zuranolone was approved by the FDA for the treatment of PPD [191].”
Rated minor: it would not touch a result — a value no result rests on, a p-value that stays on the same side of the significance level, or a conflict that is clerical, resolved elsewhere in the paper, or outside its own findings.
In the paper
§ Pharmacotherapies Targeting GABA-Glutamate Neurotransmission for Treatment-Resistant Depression > Abstract
“Of the compounds reviewed here, three are approved by the Food and Drug Administration (FDA): esketamine (Spravato) for TRD, Auvelity (dextromethorphan-bupropion) for major depressive disorder (MDD), and brexanolone (Zulresso) for post-partum depression (PPD).”
§ Pharmacotherapies Targeting GABA-Glutamate Neurotransmission for Treatment-Resistant Depression > 5. Clinical Studies with GABA Modulation in TRD > GABAA Receptor Positive Modulation
“Due to those very recent findings, Zuranolone was approved by the FDA for the treatment of PPD [191].”
Rated minor: it would not touch a result — a value no result rests on, a p-value that stays on the same side of the significance level, or a conflict that is clerical, resolved elsewhere in the paper, or outside its own findings.
In the paper
§ Pharmacotherapies Targeting GABA-Glutamate Neurotransmission for Treatment-Resistant Depression > 3. Methods: Clinical Studies of Investigational Compounds Targeting Glutamate and GABA
“All proceeding compounds demonstrate evidence of antidepressant efficacy in at least one successful clinical trial, though not all have progressed through the final stages of drug development.”
§ Pharmacotherapies Targeting GABA-Glutamate Neurotransmission for Treatment-Resistant Depression > 4. Clinical Studies with Glutamate Modulators in TRD > 4.1. Ketamine and Similar Compounds
“At 6 weeks, decreases in MADRS scores were noted from baseline, but without reaching statistical significance when compared to the placebo group, failing the primary endpoint, and, for the secondary endpoints, mood and functioning and cognitive impairment, it has also failed in separate from the placebo group.”
Citations
Cites
The Brain's Default Network: Anatomy, Function, and Relevance to Disease
Buckner, R. L., Andrews‐Hanna, J. R., & Schacter, D. L. (2008) · Annals of the New York Academy of Sciences · doi:10.1196/annals.1440.011 · Cited by 9,761
Molecular Mechanisms of Depression: Perspectives on New Treatment Strategies
Lang, U. E., & Borgwardt, S. (2013) · Cellular Physiology and Biochemistry · doi:10.1159/000350094 · Cited by 8,475
Rush, A. J., Trivedi, M. H., Wisniewski, S. R., Nierenberg, A. A., Stewart, J. W., Warden, D., Niederehe, G., Thase, M. E., Lavori, P. W., Lebowitz, B. D., et al. (2006) · American Journal of Psychiatry · doi:10.1176/ajp.2006.163.11.1905 · Cited by 5,643
Antidepressant effects of ketamine in depressed patients
Berman, R. M., Cappiello, A., Anand, A., Oren, D. A., Heninger, G. R., Charney, D. S., & Krystal, J. H. (2000) · Biological Psychiatry · doi:10.1016/s0006-3223(99)00230-9 · Cited by 3,856 · cited 3×
“Diverse NMDA receptor antagonism has demonstrated rapid antidepressant efficacy in preclinical depression paradigms [24,29,70,71] and in some clinical trials [72,73].”
BackgroundA randomized trial of an N-methyl-D-aspartate antagonist in treatment-resistant major depression.
Zarate, C. A., Singh, J. B., Carlson, P. J., Brutsche, N. E., Ameli, R., Luckenbaugh, D. A., Charney, D. S., & Manji, H. K. (2006) · Archives of General Psychiatry · doi:10.1001/archpsyc.63.8.856 · Cited by 3,766 · cited 2×
“Diverse NMDA receptor antagonism has demonstrated rapid antidepressant efficacy in preclinical depression paradigms [24,29,70,71] and in some clinical trials [72,73].”
BackgroundResultNichols, D. E. (2016) · Pharmacological Reviews · doi:10.1124/pr.115.011478 · Cited by 1,762 · cited 1×
“…glutamate/BDNF signaling via TrkB. Notably, multiple serotonergic hallucino-gens have also demonstrated preliminary efficacy in TRD [55,56] and impart downstream glutamatergic effects (as well as robust spinogenesis and dendritogenesis), which are dependent on intact TrkB signaling [57,58].”
BackgroundSynaptic plasticity and depression: new insights from stress and rapid-acting antidepressants
Duman, R. S., Aghajanian, G. K., Sanacora, G., & Krystal, J. H. (2016) · Nature Medicine · doi:10.1038/nm.4050 · Cited by 1,750 · cited 2×
“In depressed patients, synaptic plasticity pathways have been shown to be disrupted in the PFC and hippocampi, correlated with α -amino-3-hydroxy-5-methyl-4-isoxazolepropionic acid (AMPA) and NMDA receptor abnormalities [45,46].”
BackgroundHow Inhibition Shapes Cortical Activity
Isaacson, J. S., & Scanziani, M. (2011) · Neuron · doi:10.1016/j.neuron.2011.09.027 · Cited by 1,678
Synaptic Dysfunction in Depression: Potential Therapeutic Targets
Duman, R. S., & Aghajanian, G. K. (2012) · Science · doi:10.1126/science.1222939 · Cited by 1,651
Psychedelics promote structural and functional neural plasticity
Ly, C., Greb, A. C., Cameron, L. P., Wong, J. M., Barragan, E. V., Wilson, P. C., Burbach, K. F., Soltanzadeh Zarandi, S., Sood, A., Paddy, M. R., et al. (2018) · Cell Reports · doi:10.1016/j.celrep.2018.05.022 · Cited by 1,207 · cited 1×
“…glutamate/BDNF signaling via TrkB. Notably, multiple serotonergic hallucino-gens have also demonstrated preliminary efficacy in TRD [55,56] and impart downstream glutamatergic effects (as well as robust spinogenesis and dendritogenesis), which are dependent on intact TrkB signaling [57,58].”
BackgroundMurrough, J. W., Iosifescu, D. V., Chang, L. C., Al Jurdi, R. K., Green, C. E., Perez, A. M., Iqbal, S., Pillemer, S., Foulkes, A., Shah, A., et al. (2013) · American Journal of Psychiatry · doi:10.1176/appi.ajp.2013.13030392 · Cited by 1,205
Mechanisms of ketamine action as an antidepressant
Zanos, P., & Gould, T. D. (2018) · Molecular Psychiatry · doi:10.1038/mp.2017.255 · Cited by 1,127 · cited 1×
“Comparable results have been replicated in several similarly designed RDBPCTs examining single administration of sub-anesthetic dose ketamine in patients with MDD and TRD [73,91–93].”
ResultDuman, R. S., Sanacora, G., & Krystal, J. H. (2019) · Neuron · doi:10.1016/j.neuron.2019.03.013 · Cited by 1,026 · cited 4×
“BDNF knockout mice also show reduced responsiveness to such therapies [3,49].”
BackgroundInfluentialMedication Augmentation after the Failure of SSRIs for Depression
Trivedi, M. H., Fava, M., Wisniewski, S. R., Thase, M. E., Quitkin, F., Warden, D., Ritz, L., Nierenberg, A. A., Lebowitz, B. D., Biggs, M. M., et al. (2006) · New England Journal of Medicine · doi:10.1056/nejmoa052964 · Cited by 1,002 · cited 2×
“Overall, Treatment Resistant Depression (TRD) is associated with several comorbid features, including prolonged mental and physical dysfunction, increased healthcare spending, worse clinical outcomes, and a higher risk of suicide [4,6–9].”
BackgroundPsilocybin with psychological support for treatment-resistant depression: six-month follow-up
Carhart-Harris, R. L., Bolstridge, M., Day, C. M. J., Rucker, J., Watts, R., Erritzoe, D. E., Kaelen, M., Giribaldi, B., Bloomfield, M., Pilling, S., et al. (2018) · Psychopharmacology · doi:10.1007/s00213-017-4771-x · Cited by 970 · cited 2×
“…of endogenous glutamate/BDNF signaling via TrkB. Notably, multiple serotonergic hallucino-gens have also demonstrated preliminary efficacy in TRD [55,56] and impart downstream glutamatergic effects (as well as robust spinogenesis and dendritogenesis), which are dependent on intact TrkB signaling…”
BackgroundPopova, V., Daly, E. J., Trivedi, M., Cooper, K., Lane, R., Lim, P., Mazzucco, C., Hough, D., Thase, M. E., Shelton, R. C., et al. (2019) · American Journal of Psychiatry · doi:10.1176/appi.ajp.2019.19020172 · Cited by 904 · cited 2×
“Based on positive phase II results, Popova and colleagues hypothesized a far greater effect size than what manifested from their trial, possibly related to unsuccessfully blinding esketamine’s subjective effects, especially in comparison to inactive placebo [110].”
BackgroundKoolschijn, P. C. M. P., van Haren, N. E. M., Lensvelt‐Mulders, G. J. L. M., Hulshoff Pol, H. E., & Kahn, R. S. (2009) · Human Brain Mapping · doi:10.1002/hbm.20801 · Cited by 902 · cited 1×
“As extracellular glutamate release outpaces clearance by glial cells, and the ensuing inflammation and neurodegeneration likely contribute to the acute volume reductions and other cytoarchitectural abnormalities detected in depressed patients’ brains [35].”
BackgroundPalhano-Fontes, F., Barreto, D., Onias, H., Andrade, K. C., Novaes, M. M., Pessoa, J. A., Mota-Rolim, S. A., Osório, F. L., Sanches, R., dos Santos, R. G., et al. (2019) · Psychological Medicine · doi:10.1017/s0033291718001356 · Cited by 852 · cited 2×
“…of endogenous glutamate/BDNF signaling via TrkB. Notably, multiple serotonergic hallucino-gens have also demonstrated preliminary efficacy in TRD [55,56] and impart downstream glutamatergic effects (as well as robust spinogenesis and dendritogenesis), which are dependent on intact TrkB signaling…”
BackgroundDaly, E. J., Trivedi, M. H., Janik, A., Li, H., Zhang, Y., Li, X., Lane, R., Lim, P., Duca, A. R., Hough, D., et al. (2019) · JAMA Psychiatry · doi:10.1001/jamapsychiatry.2019.1189 · Cited by 795
Meltzer-Brody, S., Colquhoun, H., Riesenberg, R., Epperson, C. N., Deligiannidis, K. M., Rubinow, D. R., Li, H., Sankoh, A. J., Clemson, C., Schacterle, A., et al. (2018) · The Lancet · doi:10.1016/s0140-6736(18)31551-4 · Cited by 795 · cited 2×
“Extended release (60 h IV infusion) BRX demonstrated rapid, durable AD efficacy during phase I, II, and III clinical trials [181–183].”
BackgroundFunctional antagonists at the NMDA receptor complex exhibit antidepressant actions
Trullas, R., & Skolnick, P. (1990) · European Journal of Pharmacology · doi:10.1016/0014-2999(90)90204-j · Cited by 785 · cited 1×
“The possibility of development of antidepressant medications targeting the NMDA complex was suggested decades ago [47].”
BackgroundKetamine Pharmacology: An Update ( Pharmacodynamics and Molecular Aspects, Recent Findings )
Mion, G., & Villevieille, T. (2013) · CNS Neuroscience & Therapeutics · doi:10.1111/cns.12099 · Cited by 711
Wilkinson, S. T., Ballard, E. D., Bloch, M. H., Mathew, S. J., Murrough, J. W., Feder, A., Sos, P., Wang, G., Zarate, C. A., & Sanacora, G. (2018) · American Journal of Psychiatry · doi:10.1176/appi.ajp.2017.17040472 · Cited by 696 · cited 2×
“Additionally, many studies are hindered by homogenous samples, short durations, and limited real-world feasibility [98,100].”
BackgroundMacQueen, G., & Frodl, T. (2011) · Molecular Psychiatry · doi:10.1038/mp.2010.80 · Cited by 665 · cited 2×
“Moreover, glutamatergic transmission appears to be a key mediator of mood, cognition, perception, and emotions associated with TRD [15].”
BackgroundAntidepressant drugs act by directly binding to TRKB neurotrophin receptors
Casarotto, P. C., Girych, M., Fred, S. M., Kovaleva, V., Moliner, R., Enkavi, G., Biojone, C., Cannarozzo, C., Sahu, M. P., Kaurinkoski, K., et al. (2021) · Cell · doi:10.1016/j.cell.2021.01.034 · Cited by 663
Zhou, H.-X., Chen, X., Shen, Y.-Q., Li, L., Chen, N.-X., Zhu, Z.-C., Castellanos, F. X., & Yan, C.-G. (2020) · NeuroImage · doi:10.1016/j.neuroimage.2019.116287 · Cited by 656 · cited 1×
“Glutamatergic and GABAergic dysfunction in the prefrontal cortex (PFC) and anterior cingulate cortex (ACC) has been extensively implicated in both MDD and TRD [16–25].”
BackgroundSustained rescue of prefrontal circuit dysfunction by antidepressant-induced spine formation
Moda-Sava, R. N., Murdock, M. H., Parekh, P. K., Fetcho, R. N., Huang, B. S., Huynh, T. N., Witztum, J., Shaver, D. C., Rosenthal, D. L., Alway, E. J., et al. (2019) · Science · doi:10.1126/science.aat8078 · Cited by 643 · cited 1×
“However, glutamate-induced synaptogenesis in their study played a critical role in sustaining the effects over the subsequent week [80].”
BackgroundLu, Y.-M., Jia, Z., Janus, C., Henderson, J. T., Gerlai, R., Wojtowicz, J. M., & Roder, J. C. (1997) · The Journal of Neuroscience · doi:10.1523/jneurosci.17-13-05196.1997 · Cited by 634 · cited 1×
“In this capacity, learning performance and response depend on the frequency of mGluR 5 expression in the hippocampus [38,39].”
BackgroundFedgchin, M., Trivedi, M., Daly, E. J., Melkote, R., Lane, R., Lim, P., Vitagliano, D., Blier, P., Fava, M., Liebowitz, M., et al. (2019) · International Journal of Neuropsychopharmacology · doi:10.1093/ijnp/pyz039 · Cited by 606 · cited 1×
“Fedgchin’s group conducted an analogous study, which did not support adjunctive esketamine’s AD efficacy for TRD [111].”
ResultDepression, rumination and the default network
Berman, M. G., Peltier, S., Nee, D. E., Kross, E., Deldin, P. J., & Jonides, J. (2011) · Social Cognitive and Affective Neuroscience · doi:10.1093/scan/nsq080 · Cited by 568 · cited 1×
“In TRD specifically, rostral ACC function may mediate the balance between negative rumination and constructive self-evaluation, both facilitated by the DMN [17,22], suggesting that ACC dysfunction plays a role in excessive negative rumination.”
BackgroundPersonality, Well-Being, and Health*
Friedman, H. S., & Kern, M. L. (2014) · Annual Review of Psychology · doi:10.1146/annurev-psych-010213-115123 · Cited by 530 · cited 1×
“Overall, Treatment Resistant Depression (TRD) is associated with several comorbid features, including prolonged mental and physical dysfunction, increased healthcare spending, worse clinical outcomes, and a higher risk of suicide [4,6–9].”
BackgroundAttenuation of Antidepressant Effects of Ketamine by Opioid Receptor Antagonism
Williams, N. R., Heifets, B. D., Blasey, C., Sudheimer, K., Pannu, J., Pankow, H., Hawkins, J., Birnbaum, J., Lyons, D. M., Rodriguez, C. I., et al. (2018) · American Journal of Psychiatry · doi:10.1176/appi.ajp.2018.18020138 · Cited by 519 · cited 1×
“Both systems appear essential, though not independently sufficient, to induce ketamine’s AD action [81–83].”
BackgroundTargeting glutamate signalling in depression: progress and prospects
Murrough, J. W., Abdallah, C. G., & Mathew, S. J. (2017) · Nature Reviews Drug Discovery · doi:10.1038/nrd.2017.16 · Cited by 482 · cited 1×
“Ionotropic glutamate receptors also play a vital role in synaptic plasticity [44].”
BackgroundOchs-Ross, R., Daly, E. J., Zhang, Y., Lane, R., Lim, P., Morrison, R. L., Hough, D., Manji, H., Drevets, W. C., Sanacora, G., et al. (2020) · The American Journal of Geriatric Psychiatry · doi:10.1016/j.jagp.2019.10.008 · Cited by 481 · cited 1×
“Results from two 28-day phase III RCTs support multi-dose, adjunctive esketamine’s tolerability and AD efficacy in adult and geriatric samples [109,110].”
BackgroundBrexanolone (SAGE-547 injection) in post-partum depression: a randomised controlled trial.
Kanes, S., Colquhoun, H., Gunduz-Bruce, H., Raines, S., Arnold, R., Schacterle, A., Doherty, J., Epperson, C. N., Deligiannidis, K. M., Riesenberg, R., et al. (2017) · The Lancet · doi:10.1016/s0140-6736(17)31264-3 · Cited by 479 · cited 1×
“Extended release (60 h IV infusion) BRX demonstrated rapid, durable AD efficacy during phase I, II, and III clinical trials [181–183].”
BackgroundΔFosB in brain reward circuits mediates resilience to stress and antidepressant responses
Vialou, V., Robison, A. J., LaPlant, Q. C., Covington, H. E., Dietz, D. M., Ohnishi, Y. N., Mouzon, E., Rush, A. J., Watts, E. L., Wallace, D. L., et al. (2010) · Nature Neuroscience · doi:10.1038/nn.2551 · Cited by 479
Psychedelics promote plasticity by directly binding to BDNF receptor TrkB
Moliner, R., Girych, M., Brunello, C. A., Kovaleva, V., Biojone, C., Enkavi, G., Antenucci, L., Kot, E. F., Goncharuk, S. A., Kaurinkoski, K., et al. (2023) · Nature Neuroscience · doi:10.1038/s41593-023-01316-5 · Cited by 478 · cited 2×
“It has recently been demonstrated that conventional antidepressants such as fluoxetine and imipramine, as well as the rapid-acting glutamatergic agent ketamine, directly bind to TrkB and allosterically potentiate BDNF signaling [52,54].”
BackgroundKraus, C., Castrén, E., Kasper, S., & Lanzenberger, R. (2017) · Neuroscience & Biobehavioral Reviews · doi:10.1016/j.neubiorev.2017.03.007 · Cited by 471
Banasr, M., Chowdhury, G. M. I., Terwilliger, R., Newton, S. S., Duman, R. S., Behar, K. L., & Sanacora, G. (2010) · Molecular Psychiatry · doi:10.1038/mp.2008.106 · Cited by 458 · cited 1×
“Riluzole also increases glutamate–glutamine cycling, a potential explanation for in vitro observations of enhanced neuroplasticity and amelioration of excitotoxicity [176,177], as well as in vivo reductions in depressive behaviors [144,178].”
BackgroundBahji, A., Vazquez, G. H., & Zarate, C. A. (2021) · Journal of Affective Disorders · doi:10.1016/j.jad.2020.09.071 · Cited by 408
Beneyto, M., Kristiansen, L. V., Oni-Orisan, A., McCullumsmith, R. E., & Meador-Woodruff, J. H. (2007) · Neuropsychopharmacology · doi:10.1038/sj.npp.1301312 · Cited by 408 · cited 1×
“In depressed patients, synaptic plasticity pathways have been shown to be disrupted in the PFC and hippocampi, correlated with α -amino-3-hydroxy-5-methyl-4-isoxazolepropionic acid (AMPA) and NMDA receptor abnormalities [45,46].”
BackgroundIs it time to reassess the BDNF hypothesis of depression?
Groves, J. O. (2007) · Molecular Psychiatry · doi:10.1038/sj.mp.4002075 · Cited by 404 · cited 2×
“Further caveats to this hypothesis exist as well, and it is important to place any BDNF-related findings within the context of population heterogeneity and neuro-regional specificity [50,53].”
BackgroundA Double-Blind, Placebo-Controlled Study of Memantine in the Treatment of Major Depression
Zarate, C. A., Singh, J. B., Quiroz, J. A., De Jesus, G., Denicoff, K. K., Luckenbaugh, D. A., Manji, H. K., & Charney, D. S. (2006) · American Journal of Psychiatry · doi:10.1176/appi.ajp.163.1.153 · Cited by 387 · cited 1×
“In all reports, initial efficacy was either transient or inconsistent in larger studies [97,103,144–146].”
ResultConsolidation of Human Motor Cortical Neuroplasticity by D-Cycloserine
Nitsche, M. A., Jaussi, W., Liebetanz, D., Lang, N., Tergau, F., & Paulus, W. (2004) · Neuropsychopharmacology · doi:10.1038/sj.npp.1300517 · Cited by 385 · cited 1×
“Studies using transcranial direct current stimulation (tDCS) have shown that DCS modulates neuroplasticity through long-term potentiation via action on cortical NMDA receptors in humans [168,169].”
BackgroundFu, D.-J., Ionescu, D. F., Li, X., Lane, R., Lim, P., Sanacora, G., Hough, D., Manji, H., Drevets, W. C., & Canuso, C. M. (2020) · The Journal of Clinical Psychiatry · doi:10.4088/jcp.19m13191 · Cited by 376 · cited 2×
“In fact, with seven suicide attempts and one completion by a patient who had received esketamine just three days prior, Fu and colleagues’ findings may draw a troubling parallel to SSRI black box warnings [104].”
BackgroundDuman, R. S., & Li, N. (2012) · Philosophical Transactions of the Royal Society B: Biological Sciences · doi:10.1098/rstb.2011.0357 · Cited by 362 · cited 1×
“Diverse NMDA receptor antagonism has demonstrated rapid antidepressant efficacy in preclinical depression paradigms [24,29,70,71] and in some clinical trials [72,73].”
BackgroundPoulter, M. O., Du, L., Weaver, I. C. G., Palkovits, M., Faludi, G., Merali, Z., Szyf, M., & Anisman, H. (2008) · Biological Psychiatry · doi:10.1016/j.biopsych.2008.05.028 · Cited by 331 · cited 1×
“Likewise, reductions in both GABA A and GABA B receptor-mediated inhibition in MDD have been demonstrated across genomic [64], postmortem [65], and neuroimaging studies [28,48].”
BackgroundDuman, R. S., Deyama, S., & Fogaça, M. V. (2021) · European Journal of Neuroscience · doi:10.1111/ejn.14630 · Cited by 321 · cited 2×
“Further caveats to this hypothesis exist as well, and it is important to place any BDNF-related findings within the context of population heterogeneity and neuro-regional specificity [50,53].”
BackgroundWajs, E., Aluisio, L., Holder, R., Daly, E. J., Lane, R., Lim, P., George, J. E., Morrison, R. L., Sanacora, G., Young, A. H., et al. (2020) · The Journal of Clinical Psychiatry · doi:10.4088/jcp.19m12891 · Cited by 308 · cited 3×
“Although interpreted by the investigator as unrelated to esketamine, the suicide completer had no history of suicidal behavior or intent [113].”
BackgroundResultInfluentialNeurosteroids as novel antidepressants and anxiolytics: GABA-A receptors and beyond
Zorumski, C. F., Paul, S. M., Covey, D. F., & Mennerick, S. (2019) · Neurobiology of Stress · doi:10.1016/j.ynstr.2019.100196 · Cited by 305 · cited 3×
“A new class of robust antidepressants have evolved from the endogenous neuroactive steroid/neurosteroid (NAS) and potent GABA A PAM (Positive Allosteric Modulator) allopregnanolone (ALLO) [11,24].”
BackgroundNeuronal plasticity and neurotrophic factors in drug responses
Castrén, E., & Antila, H. (2017) · Molecular Psychiatry · doi:10.1038/mp.2017.61 · Cited by 284 · cited 1×
“Increasing evidence suggests that BDNF-TrkB signaling underlies a substantial portion of both affective pathophysiology and treatment response across therapeutic approaches [51,52].”
BackgroundGarakani, A., Jaffe, R. J., Savla, D., Welch, A. K., Protin, C. A., Bryson, E. O., & McDowell, D. M. (2016) · The American Journal on Addictions · doi:10.1111/ajad.12372 · Cited by 279 · cited 1×
“Concerns regarding toxicity and abuse risk, which mostly occur with chronic, high-dose recreational usage, have somewhat obscured promising initial findings [128].”
BackgroundHorn (2010) · Frontiers in Systems Neuroscience · doi:10.3389/fnsys.2010.00033 · Cited by 276
Opposite Molecular Signatures of Depression in Men and Women
Seney, M. L., Huo, Z., Cahill, K., French, L., Puralewski, R., Zhang, J., Logan, R. W., Tseng, G., Lewis, D. A., & Sibille, E. (2018) · Biological Psychiatry · doi:10.1016/j.biopsych.2018.01.017 · Cited by 272
Papp, M., & Moryl, E. (1994) · European Journal of Pharmacology · doi:10.1016/0014-2999(94)90516-9 · Cited by 272 · cited 1×
“Diverse NMDA receptor antagonism has demonstrated rapid antidepressant efficacy in preclinical depression paradigms [24,29,70,71] and in some clinical trials [72,73].”
BackgroundPrice, R. B., Shungu, D. C., Mao, X., Nestadt, P., Kelly, C., Collins, K. A., Murrough, J. W., Charney, D. S., & Mathew, S. J. (2009) · Biological Psychiatry · doi:10.1016/j.biopsych.2008.10.025 · Cited by 270 · cited 2×
“In the CNS, reductions in ACC GABA levels appear to correlate with increased anhedonia and treatment resistance [19,23].”
BackgroundEvidence of Cortical Inhibitory Deficits in Major Depressive Disorder
Levinson, A. J., Fitzgerald, P. B., Favalli, G., Blumberger, D. M., Daigle, M., & Daskalakis, Z. J. (2010) · Biological Psychiatry · doi:10.1016/j.biopsych.2009.09.025 · Cited by 261
Intravenous arketamine for treatment-resistant depression: open-label pilot study
Leal, G. C., Bandeira, I. D., Correia-Melo, F. S., Telles, M., Mello, R. P., Vieira, F., Lima, C. S., Jesus-Nunes, A. P., Guerreiro-Costa, L. N. F., Marback, R. F., et al. (2021) · European Archives of Psychiatry and Clinical Neuroscience · doi:10.1007/s00406-020-01110-5 · Cited by 257 · cited 1×
“Arketamine (R(-)-ketamine, PCN-101) has demonstrated results in its first open-label study delivering single IV infusion to seven TRD patients [121].”
BackgroundZarate, C. A., Mathews, D., Ibrahim, L., Chaves, J. F., Marquardt, C., Ukoh, I., Jolkovsky, L., Brutsche, N. E., Smith, M. A., & Luckenbaugh, D. A. (2013) · Biological Psychiatry · doi:10.1016/j.biopsych.2012.10.019 · Cited by 255 · cited 1×
“Other exploratory AD compounds that exemplify NMDAR antagonism without ke-tamine’s associated psychotomimetic and dissociative properties include memantine [131], lanicemine [142], and CERC 301 [143].”
BackgroundKetamine: NMDA Receptors and Beyond
Zorumski, C. F., Izumi, Y., & Mennerick, S. (2016) · The Journal of Neuroscience · doi:10.1523/jneurosci.1547-16.2016 · Cited by 254 · cited 1×
“Diverse NMDA receptor antagonism has demonstrated rapid antidepressant efficacy in preclinical depression paradigms [24,29,70,71] and in some clinical trials [72,73].”
BackgroundSex differences in glutamate receptor gene expression in major depression and suicide
Gray, A. L., Hyde, T. M., Deep-Soboslay, A., Kleinman, J. E., & Sodhi, M. S. (2015) · Molecular Psychiatry · doi:10.1038/mp.2015.91 · Cited by 250 · cited 1×
“In women with TRD/treatment-resistant postpartum depression, depressive severity is linked to GABA concentrations in the DMN [26,27].”
BackgroundGlutamate Receptors and Nociception: Implications for the Drug Treatment of Pain
Fundytus, M. E. (2001) · CNS Drugs · doi:10.2165/00023210-200115010-00004 · Cited by 250 · cited 1×
“Both systems appear essential, though not independently sufficient, to induce ketamine’s AD action [81–83].”
BackgroundKetamine has distinct electrophysiological and behavioral effects in depressed and healthy subjects
Nugent, A. C., Ballard, E. D., Gould, T. D., Park, L. T., Moaddel, R., Brutsche, N. E., & Zarate, C. A. (2019) · Molecular Psychiatry · doi:10.1038/s41380-018-0028-2 · Cited by 250 · cited 1×
“In that regard, lower baseline gamma power (reflective of GABA and glutamate functional balance) and subsequent elevation after ketamine administration have been shown to predict better antidepressant responses in TRD [88], though further validation is needed.”
BackgroundMolecular mechanisms underlying the antidepressant actions of arketamine: beyond the NMDA receptor
Wei, Y., Chang, L., & Hashimoto, K. (2022) · Molecular Psychiatry · doi:10.1038/s41380-021-01121-1 · Cited by 248 · cited 1×
“For now, the therapeutic primacy of NMDAR inhibition and resultant AMPAR potentiation appears a temporary frontrunner in the dynamic glutamatergic antidepressant landscape [75,76].”
BackgroundSanacora, G., & Banasr, M. (2013) · Biological Psychiatry · doi:10.1016/j.biopsych.2013.03.032 · Cited by 239 · cited 3×
“Subjects with depression have been shown to display a variety of glutamatergic abnormalities, including reduced glial density, decreased expression of the glutamate reuptake transporters EAAT1 and EAAT2 and decreased enzymatic conversion from glutamate to glutamine [33].”
BackgroundInfluentialNitrous Oxide for Treatment-Resistant Major Depression: A Proof-of-Concept Trial
Nagele, P., Duma, A., Kopec, M., Gebara, M. A., Parsoei, A., Walker, M., Janski, A., Panagopoulos, V. N., Cristancho, P., Miller, J. P., et al. (2015) · Biological Psychiatry · doi:10.1016/j.biopsych.2014.11.016 · Cited by 230 · cited 1×
“Nagele and colleagues’ proof-of-concept RCT tested the antidepressant effects a single session of nitrous oxide inhalation in TRD subjects and reported substantial, rapidly onset AD effects with fewer adverse outcomes than anticipated [99,126].”
BackgroundIbrahim, L., DiazGranados, N., Jolkovsky, L., Brutsche, N., Luckenbaugh, D. A., Herring, W. J., Potter, W. Z., & Zarate, C. A. (2012) · Journal of Clinical Psychopharmacology · doi:10.1097/jcp.0b013e31825d70d6 · Cited by 220 · cited 1×
“Other exploratory AD compounds that exemplify NMDAR antagonism without ke-tamine’s associated psychotomimetic and dissociative properties include memantine [131], lanicemine [142], and CERC 301 [143].”
BackgroundRole of adult hippocampal neurogenesis in stress resilience
Levone, B. R., Cryan, J. F., & O'Leary, O. F. (2015) · Neurobiology of Stress · doi:10.1016/j.ynstr.2014.11.003 · Cited by 218 · cited 1×
“This process may ultimately facilitate hippocampal neurogenesis and normalize hypothalamic–pituitary– adrenal (HPA) axis activity, two processes that have been repeatedly implicated in recovery from depression [42,43].”
BackgroundAnterior Cingulate Cortexγ-Aminobutyric Acid in Depressed Adolescents: Relationship to Anhedonia
Gabbay, V. (2012) · Archives of General Psychiatry · doi:10.1001/archgenpsychiatry.2011.131 · Cited by 201 · cited 2×
“In the CNS, reductions in ACC GABA levels appear to correlate with increased anhedonia and treatment resistance [19,23].”
BackgroundPRESKORN, S., MACALUSO, M., MEHRA, D. V., ZAMMIT, G., MOSKAL, J. R., & BURCH, R. M. (2015) · Journal of Psychiatric Practice · doi:10.1097/01.pra.0000462606.17725.93 · Cited by 193 · cited 1×
“Based on safety and efficacy data obtained in phase I and II trials [164], rapastinel is not associated with ketamine-like dissociation and was granted fast track status and later breakthrough therapy designation for MDD in 2016 [161].”
BackgroundCorreia-Melo, F. S., Leal, G. C., Vieira, F., Jesus-Nunes, A. P., Mello, R. P., Magnavita, G., Caliman-Fontes, A. T., Echegaray, M. V. F., Bandeira, I. D., Silva, S. S., et al. (2020) · Journal of Affective Disorders · doi:10.1016/j.jad.2019.11.086 · Cited by 193
Zuranolone for the Treatment of Postpartum Depression
Deligiannidis, K. M., Meltzer-Brody, S., Maximos, B., Peeper, E. Q., Freeman, M., Lasser, R., Bullock, A., Kotecha, M., Li, S., Forrestal, F., et al. (2023) · American Journal of Psychiatry · doi:10.1176/appi.ajp.20220785 · Cited by 192 · cited 1×
“Another very recent phase III trial compared Zuranolone versus placebo in 196 patients, showing significant positive results in improving depressive symptoms on patients with PPD on days 3, 15, 28, and 45 [190].”
ResultReduced somatostatin in subgenual anterior cingulate cortex in major depression
Tripp, A., Kota, R. S., Lewis, D. A., & Sibille, E. (2011) · Neurobiology of Disease · doi:10.1016/j.nbd.2011.01.014 · Cited by 190
Yang, C., Yang, J., Luo, A., & Hashimoto, K. (2019) · Translational Psychiatry · doi:10.1038/s41398-019-0624-1 · Cited by 190 · cited 1×
“For now, the therapeutic primacy of NMDAR inhibition and resultant AMPAR potentiation appears a temporary frontrunner in the dynamic glutamatergic antidepressant landscape [75,76].”
BackgroundPizzagalli, D. A., Webb, C. A., Dillon, D. G., Tenke, C. E., Kayser, J., Goer, F., Fava, M., McGrath, P., Weissman, M., Parsey, R., et al. (2018) · JAMA Psychiatry · doi:10.1001/jamapsychiatry.2018.0252 · Cited by 189 · cited 3×
“In both MDD and TRD, region-specific normalization of GABA concentrations in the occipital cortex (OCC), ACC, and DMN have repeatedly been observed in response to all successful antidepressant therapies [19,22,23,63].”
BackgroundThe effect of intravenous, intranasal, and oral ketamine in mood disorders: A meta-analysis
McIntyre, R. S., Carvalho, I. P., Lui, L. M. W., Majeed, A., Masand, P. S., Gill, H., Rodrigues, N. B., Lipsitz, O., Coles, A. C., Lee, Y., et al. (2020) · Journal of Affective Disorders · doi:10.1016/j.jad.2020.06.050 · Cited by 187 · cited 1×
“Meta-analyses consistently support these findings [91,92,94], establishing ketamine’s AD efficacy in oral and intranasal administration, repeated dosing, an augmenting agent, and patients with treatment-resistant bipolar depression or suicidal ideation [91,94–96].”
BackgroundEvans, J., Sun, Y., McGregor, A., & Connor, B. (2012) · Neuropharmacology · doi:10.1016/j.neuropharm.2012.08.012 · Cited by 184 · cited 3×
“In both MDD and TRD, region-specific normalization of GABA concentrations in the occipital cortex (OCC), ACC, and DMN have repeatedly been observed in response to all successful antidepressant therapies [19,22,23,63].”
BackgroundModulation of the antidepressant effects of ketamine by the mTORC1 inhibitor rapamycin
Abdallah, C. G., Averill, L. A., Gueorguieva, R., Goktas, S., Purohit, P., Ranganathan, M., Sherif, M., Ahn, K.-H., D’Souza, D. C., Formica, R., et al. (2020) · Neuropsychopharmacology · doi:10.1038/s41386-020-0644-9 · Cited by 184 · cited 1×
“First, contrary to preclinical observations, a recent randomized controlled trial (RCT) in humans demonstrated prolonged antidepressant responses to ketamine with coadministration of rapamycin (mTOR inhibitor) [79].”
ResultA randomized add-on trial of high-dose d-cycloserine for treatment-resistant depression
Heresco-Levy, U., Gelfin, G., Bloch, B., Levin, R., Edelman, S., Javitt, D. C., & Kremer, I. (2013) · International Journal of Neuropsychopharmacology · doi:10.1017/s1461145712000910 · Cited by 177 · cited 1×
“The same group of researchers later conducted a larger ( n = 26) RCT, in which high-dose DCS augmentation showed superior AD efficacy to placebo [171].”
BackgroundMechanisms of ketamine and its metabolites as antidepressants
Hess, E. M., Riggs, L. M., Michaelides, M., & Gould, T. D. (2022) · Biochemical Pharmacology · doi:10.1016/j.bcp.2021.114892 · Cited by 175 · cited 1×
“Such complex effects seem to ultimately result in increased neurogenesis and synaptogenesis, improved neuroplasticity, and normalization of stress-related neurodegeneration [77,78].”
BackgroundAttenuation of antidepressant and antisuicidal effects of ketamine by opioid receptor antagonism
Williams, N. R., Heifets, B. D., Bentzley, B. S., Blasey, C., Sudheimer, K. D., Hawkins, J., Lyons, D. M., & Schatzberg, A. F. (2019) · Molecular Psychiatry · doi:10.1038/s41380-019-0503-4 · Cited by 174 · cited 1×
“Some (but not all) studies have demonstrated attenuation of ketamine’s AD efficacy with coadministration of naltrexone, a non-selective opioid receptor antagonist, again necessitating further replication [84,85].”
BackgroundEvans, J. W., Szczepanik, J., Brutsché, N., Park, L. T., Nugent, A. C., & Zarate, C. A. (2018) · Biological Psychiatry · doi:10.1016/j.biopsych.2018.01.027 · Cited by 173 · cited 1×
“…also appears to reconfigure functional connectivity within the DMN. Notably, normalization of insular DMN hyperactivity in TRD patients appears to coincide with peak antidepressant responses (48 h), subsequently reversing at 10 days post-infusion (when effects on mood are typically lost) [89].”
BackgroundBrennan, B. P., Hudson, J. I., Jensen, J. E., McCarthy, J., Roberts, J. L., Prescot, A. P., Cohen, B. M., Pope, H. G., Renshaw, P. F., & Öngür, D. (2010) · Neuropsychopharmacology · doi:10.1038/npp.2009.191 · Cited by 168 · cited 1×
“Riluzole also increases glutamate–glutamine cycling, a potential explanation for in vitro observations of enhanced neuroplasticity and amelioration of excitotoxicity [176,177], as well as in vivo reductions in depressive behaviors [144,178].”
BackgroundGlutamine in the central nervous system: function and dysfunction
Albrecht, J. (2007) · Frontiers in Bioscience · doi:10.2741/2067 · Cited by 168 · cited 1×
“To counteract these effects, glial cells are responsible for glutamate reuptake and facilitate the glial–astrocytic conversion of glutamate to glutamine, which limits excitotoxicity and provides necessary precursors for GABA synthesis [36].”
BackgroundGlutamatergic Neurotransmission: Pathway to Developing Novel Rapid-Acting Antidepressant Treatments
Kadriu, B., Musazzi, L., Henter, I. D., Graves, M., Popoli, M., & Zarate, C. A. (2019) · International Journal of Neuropsychopharmacology · doi:10.1093/ijnp/pyy094 · Cited by 165 · cited 6×
“Nuedexta is FDA-approved for pseudobulbar affect treatment, and alternative formulations designed to increase DM’s bioavailability without the risk of quinidine toxicity are under investigation [144].”
BackgroundResultInfluentialSanacora, G., & Schatzberg, A. F. (2015) · Neuropsychopharmacology · doi:10.1038/npp.2014.261 · Cited by 160
Kryst, J., Kawalec, P., Mitoraj, A. M., Pilc, A., Lasoń, W., & Brzostek, T. (2020) · Pharmacological Reports · doi:10.1007/s43440-020-00097-z · Cited by 159
Du, J., Gray, N. A., Falke, C. A., Chen, W., Yuan, P., Szabo, S. T., Einat, H., & Manji, H. K. (2004) · The Journal of Neuroscience · doi:10.1523/jneurosci.1258-04.2004 · Cited by 157 · cited 1×
“Glutamatergic modulation in depression is, to a degree, already a successful mechanism of many conventional antide-pressants (cAD), refining neurotransmission and receptor expression via direct and indirect actions with chronic use [68,69].”
BackgroundYoon, G., Petrakis, I. L., & Krystal, J. H. (2019) · JAMA Psychiatry · doi:10.1001/jamapsychiatry.2018.3990 · Cited by 155 · cited 1×
“Some (but not all) studies have demonstrated attenuation of ketamine’s AD efficacy with coadministration of naltrexone, a non-selective opioid receptor antagonist, again necessitating further replication [84,85].”
BackgroundMachado-Vieira, R., Yuan, P., Brutsche, N., DiazGranados, N., Luckenbaugh, D., Manji, H. K., & Zarate, C. A. (2009) · The Journal of Clinical Psychiatry · doi:10.4088/jcp.08m04659 · Cited by 155
Self-citationOpen-label, proof-of-concept study of brexanolone in the treatment of severe postpartum depression
Kanes, S. J., Colquhoun, H., Doherty, J., Raines, S., Hoffmann, E., Rubinow, D. R., & Meltzer-Brody, S. (2017) · Human Psychopharmacology: Clinical and Experimental · doi:10.1002/hup.2576 · Cited by 151
Arnone, D., Mumuni, A. N., Jauhar, S., Condon, B., & Cavanagh, J. (2015) · European Neuropsychopharmacology · doi:10.1016/j.euroneuro.2015.04.016 · Cited by 150 · cited 1×
“…studies demonstrated that decreased Glx levels with absolute values in the pre-frontal cortex were correlated with treatment severity (i.e., number of failed antidepressant treatments), indicating that the severity of glutamatergic dysregulation could be related to the severity of illness [34].”
BackgroundKetamine Assisted Psychotherapy: A Systematic Narrative Review of the Literature
Drozdz, S. J., Goel, A., McGarr, M. W., Katz, J. D., Ritvo, P., Mattina, G. F., Bhat, V., Diep, C., & Ladha, K. S. (2022) · Journal of Pain Research · doi:10.2147/jpr.s360733 · Cited by 149 · cited 1×
“This property may open a window during which delivery of secondary agents (or psychotherapy) can maximize and prolong beneficial adaptations [194,195].”
BackgroundHu, Y.-D., Xiang, Y.-T., Fang, J.-X., Zu, S., Sha, S., Shi, H., Ungvari, G. S., Correll, C. U., Chiu, H. F. K., Xue, Y., et al. (2016) · Psychological Medicine · doi:10.1017/s0033291715002159 · Cited by 146 · cited 2×
“In terms of sustained effects, two RCTs have shown prolonged (4–6 weeks) antidepressant effects using combined intravenous (IV) (0.5 mg/kg) and oral (50 mg/day) ketamine augmentation in MDD/TRD populations [95,96].”
BackgroundInfluentialMizuta, I., Ohta, M., Ohta, K., Nishimura, M., Mizuta, E., & Kuno, S. (2001) · Neuroscience Letters · doi:10.1016/s0304-3940(01)02098-5 · Cited by 145 · cited 1×
“Riluzole also increases glutamate–glutamine cycling, a potential explanation for in vitro observations of enhanced neuroplasticity and amelioration of excitotoxicity [176,177], as well as in vivo reductions in depressive behaviors [144,178].”
BackgroundBook Review: Metabotropic Glutamate Receptors: Electrical and Chemical Signaling Properties
Coutinho, V., & Knöpfel, T. (2002) · The Neuroscientist · doi:10.1177/1073858402238514 · Cited by 144
Dextromethorphan: An update on its utility for neurological and neuropsychiatric disorders
Nguyen, L., Thomas, K. L., Lucke-Wold, B. P., Cavendish, J. Z., Crowe, M. S., & Matsumoto, R. R. (2016) · Pharmacology & Therapeutics · doi:10.1016/j.pharmthera.2016.01.016 · Cited by 141 · cited 2×
“The unconfirmed mechanism of AD action may rely on σ 1 (“opioid-like”) receptor activation, monoamin-ergic neurotransmitter reuptake inhibition, and nicotinic acetylcholine (nACh) receptor antagonism, leading to downstream AMPAR activation [147–149].”
BackgroundTabuteau, H., Jones, A., Anderson, A., Jacobson, M., & Iosifescu, D. V. (2022) · American Journal of Psychiatry · doi:10.1176/appi.ajp.21080800 · Cited by 140 · cited 1×
“Two phase III RCTs have evaluated AXS-05 monotherapy for MDD/TRD, showing favorable safety and tolerability [155].”
BackgroundManahan-Vaughan, D., & Braunewell, K.-H. (2005) · Cerebral Cortex · doi:10.1093/cercor/bhi047 · Cited by 138 · cited 1×
“In this capacity, learning performance and response depend on the frequency of mGluR 5 expression in the hippocampus [38,39].”
BackgroundZaki, N., Chen, L., Lane, R., Doherty, T., Drevets, W. C., Morrison, R. L., Sanacora, G., Wilkinson, S. T., Popova, V., & Fu, D.-J. (2023) · Neuropsychopharmacology · doi:10.1038/s41386-023-01577-5 · Cited by 137 · cited 1×
“A very recent open-label, long-term study accessed the safety and efficacy of esketamine use in patients with TRD [114].”
BackgroundD-Cycloserine in Neuropsychiatric Diseases: A Systematic Review
Schade, S., & Paulus, W. (2016) · International Journal of Neuropsychopharmacology · doi:10.1093/ijnp/pyv102 · Cited by 135 · cited 3×
“Studies using transcranial direct current stimulation (tDCS) have shown that DCS modulates neuroplasticity through long-term potentiation via action on cortical NMDA receptors in humans [168,169].”
BackgroundGastaldon, C., Raschi, E., Kane, J. M., Barbui, C., & Schoretsanitis, G. (2021) · Psychotherapy and Psychosomatics · doi:10.1159/000510703 · Cited by 134 · cited 1×
“As detailed above, esketamine-associated adverse events across trials have raised significant concern, particularly with regard to inducing suicidality [115].”
BackgroundQuiroz, J. A., Tamburri, P., Deptula, D., Banken, L., Beyer, U., Rabbia, M., Parkar, N., Fontoura, P., & Santarelli, L. (2016) · JAMA Psychiatry · doi:10.1001/jamapsychiatry.2016.0838 · Cited by 133
Ketamine and Beyond: Investigations into the Potential of Glutamatergic Agents to Treat Depression
Lener, M. S., Kadriu, B., & Zarate, C. A. (2017) · Drugs · doi:10.1007/s40265-017-0702-8 · Cited by 131 · cited 4×
“Esketamine has nearly fourfold greater affinity for the NMDAR than (R)-ketamine but interestingly induces fewer and weaker psychotomimetic and dissociative effects [103].”
BackgroundResultInfluentialCYLOSERINE AS AN ANTIDEPRESSANT AGENT
CRANE, G. E. (1959) · American Journal of Psychiatry · doi:10.1176/ajp.115.11.1025 · Cited by 127 · cited 1×
“D-cycloserine (DCS) is a broad-spectrum antibiotic, first suggested to promote antidepressant properties in 1959 by G.E. Crane [167].”
BackgroundmGluR5 in the nucleus accumbens is critical for promoting resilience to chronic stress
Shin, S., Kwon, O., Kang, J. I., Kwon, S., Oh, S., Choi, J., Kim, C. H., & Kim, D. G. (2015) · Nature Neuroscience · doi:10.1038/nn.4028 · Cited by 125 · cited 1×
“The mGluR 5 receptor also mediates stress resilience via post-synaptic mGluR 5 activation on the nucleus accumbens [40,41].”
BackgroundMice with altered BDNF signaling as models for mood disorders and antidepressant effects
Lindholm, J. S. O., & Castrén, E. (2014) · Frontiers in Behavioral Neuroscience · doi:10.3389/fnbeh.2014.00143 · Cited by 114 · cited 1×
“BDNF knockout mice also show reduced responsiveness to such therapies [3,49].”
BackgroundAbdallah, C. G., Averill, C. L., Salas, R., Averill, L. A., Baldwin, P. R., Krystal, J. H., Mathew, S. J., & Mathalon, D. H. (2017) · Biological Psychiatry: Cognitive Neuroscience and Neuroimaging · doi:10.1016/j.bpsc.2017.04.006 · Cited by 111
Lüscher, B., & Möhler, H. (2019) · F1000Research · doi:10.12688/f1000research.18758.1 · Cited by 105 · cited 3×
“Strong evidence supports a key role for GABA in MDD, showing structural and functional GABAergic system deficits throughout the central and peripheral nervous systems [61].”
BackgroundAllopregnanolone-based treatments for postpartum depression: Why/how do they work?
Walton, N., & Maguire, J. (2019) · Neurobiology of Stress · doi:10.1016/j.ynstr.2019.100198 · Cited by 103 · cited 6×
“A new class of robust antidepressants have evolved from the endogenous neuroactive steroid/neurosteroid (NAS) and potent GABA A PAM (Positive Allosteric Modulator) allopregnanolone (ALLO) [11,24].”
BackgroundInfluentialZhao, J., Verwer, R. W. H., Gao, S.-F., Qi, X.-R., Lucassen, P. J., Kessels, H. W., & Swaab, D. F. (2018) · Journal of Psychiatric Research · doi:10.1016/j.jpsychires.2018.04.020 · Cited by 102 · cited 2×
“GABAergic deficits involve the concomitant presence of neurophysiological, neuroendocrine, cognitive, and behavioral findings [32,66,67], which may be reversed with targeted therapeutics.”
BackgroundInvolvement of Sigma-1 Receptors in the Antidepressant-like Effects of Dextromethorphan
Nguyen, L., Robson, M. J., Healy, J. R., Scandinaro, A. L., & Matsumoto, R. R. (2014) · PLoS ONE · doi:10.1371/journal.pone.0089985 · Cited by 99 · cited 1×
“Due to its short half-life, DM lacks AD efficacy as a monotherapy, but in conjunction with quinidine, a CYP2D6 enzyme inhibitor that limits DM metabolism, it produces more lasting AD effects [148,149].”
BackgroundMathai, D. S., Meyer, M. J., Storch, E. A., & Kosten, T. R. (2020) · Journal of Affective Disorders · doi:10.1016/j.jad.2019.12.023 · Cited by 97 · cited 1×
“Notably, preclinical studies suggest that this enantiomer may have important downstream signaling differences from esketamine, conferring more prolonged responses with fewer adverse effects compared to either racemic or esketamine [124].”
BackgroundKlumpers, U. M. H., Veltman, D. J., Drent, M. L., Boellaard, R., Comans, E. F. I., Meynen, G., Lammertsma, A. A., & Hoogendijk, W. J. G. (2010) · European Journal of Nuclear Medicine and Molecular Imaging · doi:10.1007/s00259-009-1292-9 · Cited by 95 · cited 2×
“These areas are highly implicated in the adverse cognitive and affective features of depression, especially rumination and anhedonia [3,48].”
BackgroundRomeo, B., Choucha, W., Fossati, P., & Rotge, J.-Y. (2018) · Journal of Psychiatry and Neuroscience · doi:10.1503/jpn.160228 · Cited by 94 · cited 1×
“Compared to healthy controls, depressed patients consistently display net reductions in cortical GABA concentrations and neuronal density, as well as decreased enzymatic synthesis in the periphery and cerebrospinal fluid (CSF) [61,62].”
BackgroundCole, J., Sohn, M. N., Harris, A. D., Bray, S. L., Patten, S. B., & McGirr, A. (2022) · JAMA Psychiatry · doi:10.1001/jamapsychiatry.2022.3255 · Cited by 93
Gill, H., Gill, B., Rodrigues, N. B., Lipsitz, O., Rosenblat, J. D., El-Halabi, S., Nasri, F., Mansur, R. B., Lee, Y., & McIntyre, R. S. (2021) · Neuroscience & Biobehavioral Reviews · doi:10.1016/j.neubiorev.2020.11.020 · Cited by 93 · cited 1×
“Lastly, contrasting the deleterious effects seen in heathy adults or chronic ketamine addiction, repeated acute phase administration of IV ketamine appears to reliably ameliorate cognitive impairment in TRD patients [86].”
BackgroundDeligiannidis, K. M., Fales, C. L., Kroll-Desrosiers, A. R., Shaffer, S. A., Villamarin, V., Tan, Y., Hall, J. E., Frederick, B. B., Sikoglu, E. M., Edden, R. A., et al. (2019) · Neuropsychopharmacology · doi:10.1038/s41386-018-0242-2 · Cited by 92 · cited 2×
“In women with TRD/treatment-resistant postpartum depression, depressive severity is linked to GABA concentrations in the DMN [26,27].”
BackgroundNovel glutamatergic agents for major depressive disorder and bipolar disorder
Machado-Vieira, R., Ibrahim, L., Henter, I. D., & Zarate, C. A. (2012) · Pharmacology Biochemistry and Behavior · doi:10.1016/j.pbb.2011.09.010 · Cited by 92 · cited 1×
“With more than 90% of CNS neurons acting through these pathways, the excitatory activity must be well-regulated by an inhibitory component [12].”
BackgroundSelf-citationYang, B., Zhang, J.-C., Han, M., Yao, W., Yang, C., Ren, Q., Ma, M., Chen, Q.-X., & Hashimoto, K. (2016) · Psychopharmacology · doi:10.1007/s00213-016-4399-2 · Cited by 91 · cited 1×
“Preclinical evidence suggests that rapastinel may enhance dendritic complexity and long-term potentiation via bidirectional modulation of NMDA signal transduction [161–163].”
BackgroundYin, H., Pantazatos, S. P., Galfalvy, H., Huang, Y., Rosoklija, G. B., Dwork, A. J., Burke, A., Arango, V., Oquendo, M. A., & Mann, J. J. (2016) · American Journal of Medical Genetics Part B: Neuropsychiatric Genetics · doi:10.1002/ajmg.b.32423 · Cited by 91 · cited 1×
“Likewise, reductions in both GABA A and GABA B receptor-mediated inhibition in MDD have been demonstrated across genomic [64], postmortem [65], and neuroimaging studies [28,48].”
BackgroundControlled trial of d-cycloserine adjuvant therapy for treatment-resistant major depressive disorder
Heresco-Levy, U., Javitt, D. C., Gelfin, Y., Gorelik, E., Bar, M., Blanaru, M., & Kremer, I. (2006) · Journal of Affective Disorders · doi:10.1016/j.jad.2006.03.004 · Cited by 89 · cited 1×
“In an initial small study of TRD patients, adjunctive DCS failed to separate from placebo in terms of AD efficacy [170].”
BackgroundArabzadeh, S., Hakkikazazi, E., Shahmansouri, N., Tafakhori, A., Ghajar, A., Jafarinia, M., & Akhondzadeh, S. (2018) · Journal of Affective Disorders · doi:10.1016/j.jad.2018.02.056 · Cited by 89 · cited 1×
“In terms of sustained effects, two RCTs have shown prolonged (4–6 weeks) antidepressant effects using combined intravenous (IV) (0.5 mg/kg) and oral (50 mg/day) ketamine augmentation in MDD/TRD populations [95,96].”
BackgroundInfluentialBurgdorf, J., Zhang, X.-L., Weiss, C., Gross, A., Boikess, S. R., Kroes, R. A., Khan, M. A., Burch, R. M., Rex, C. S., Disterhoft, J. F., et al. (2015) · Neuroscience · doi:10.1016/j.neuroscience.2015.09.004 · Cited by 88
Clayton, A. H., Lasser, R., Parikh, S. V., Iosifescu, D. V., Jung, J., Kotecha, M., Forrestal, F., Jonas, J., Kanes, S. J., & Doherty, J. (2023) · American Journal of Psychiatry · doi:10.1176/appi.ajp.20220459 · Cited by 87 · cited 1×
“A recently published phase III trial had very positive results, showing significant clinical improvements at day 3 and sustained through the whole duration of the study at day 42 [189].”
BackgroundGálvez, V., Li, A., Huggins, C., Glue, P., Martin, D., Somogyi, A. A., Alonzo, A., Rodgers, A., Mitchell, P. B., & Loo, C. K. (2018) · Journal of Psychopharmacology · doi:10.1177/0269881118760660 · Cited by 85 · cited 1×
“Additionally, many studies are hindered by homogenous samples, short durations, and limited real-world feasibility [98,100].”
BackgroundFarmer, C. A., Gilbert, J. R., Moaddel, R., George, J., Adeojo, L., Lovett, J., Nugent, A. C., Kadriu, B., Yuan, P., Gould, T. D., et al. (2020) · Neuropsychopharmacology · doi:10.1038/s41386-020-0663-6 · Cited by 85 · cited 2×
“Despite repeated and robust demonstration of antidepressant effects across animal models with R,R-HNK, higher plasma levels appear to confer less improvement in clinical studies of depression and suicidal ideation [59,60].”
BackgroundChen, M.-H., Cheng, C.-M., Gueorguieva, R., Lin, W.-C., Li, C.-T., Hong, C.-J., Tu, P.-C., Bai, Y.-M., Tsai, S.-J., Krystal, J. H., et al. (2019) · Neuropsychopharmacology · doi:10.1038/s41386-019-0480-y · Cited by 84 · cited 3×
“In all reports, initial efficacy was either transient or inconsistent in larger studies [97,103,144–146].”
BackgroundResultFava, M., Stahl, S., Pani, L., De Martin, S., Pappagallo, M., Guidetti, C., Alimonti, A., Bettini, E., Mangano, R. M., Wessel, T., et al. (2022) · American Journal of Psychiatry · doi:10.1176/appi.ajp.2021.21020197 · Cited by 83 · cited 3×
“A phase IIa RDBPCT evaluated the AD efficacy of one loading dose followed by daily oral d-methadone as an add-on to TRD patients’ existing therapies [134].”
BackgroundMethodFogaça, M. V., Fukumoto, K., Franklin, T., Liu, R.-J., Duman, C. H., Vitolo, O. V., & Duman, R. S. (2019) · Neuropsychopharmacology · doi:10.1038/s41386-019-0501-x · Cited by 82 · cited 3×
“The d-stereoisomer likewise acts as an NMDA receptor antagonist, binding at the same synaptic site as ketamine and dizocilpine (MK-801) [131,132].”
BackgroundMedeiros, G. C., Gould, T. D., Prueitt, W. L., Nanavati, J., Grunebaum, M. F., Farber, N. B., Singh, B., Selvaraj, S., Machado-Vieira, R., Achtyes, E. D., et al. (2022) · Molecular Psychiatry · doi:10.1038/s41380-022-01652-1 · Cited by 75 · cited 1×
“Importantly, BDNF has displayed adequate central–peripheral correlation, being reflective of CNS glutamatergic activity [90].”
BackgroundSelf-citationSuchting, R., Tirumalaraju, V., Gareeb, R., Bockmann, T., de Dios, C., Aickareth, J., Pinjari, O., Soares, J. C., Cowen, P. J., & Selvaraj, S. (2021) · Journal of Affective Disorders · doi:10.1016/j.jad.2021.01.021 · Cited by 73 · cited 1×
“While safety profiles have improved, a recent systematic review demonstrated that MAOIs and TCAs still retain the highest efficacy and acceptability, respectively, amongst antidepressants [192].”
BackgroundSelf-citationHomer1/mGluR5 Activity Moderates Vulnerability to Chronic Social Stress
Wagner, K. V., Hartmann, J., Labermaier, C., Häusl, A. S., Zhao, G., Harbich, D., Schmid, B., Wang, X.-D., Santarelli, S., Kohl, C., et al. (2015) · Neuropsychopharmacology · doi:10.1038/npp.2014.308 · Cited by 67 · cited 1×
“This process may ultimately facilitate hippocampal neurogenesis and normalize hypothalamic–pituitary– adrenal (HPA) axis activity, two processes that have been repeatedly implicated in recovery from depression [42,43].”
BackgroundJaeschke, G., Kolczewski, S., Spooren, W., Vieira, E., Bitter-Stoll, N., Boissin, P., Borroni, E., Büttelmann, B., Ceccarelli, S., Clemann, N., et al. (2015) · Journal of Medicinal Chemistry · doi:10.1021/jm501642c · Cited by 66 · cited 1×
“Preclinical evidence indicates robust anxiolytic and antidepressant efficacy [173].”
BackgroundPark, L. T., Kadriu, B., Gould, T. D., Zanos, P., Greenstein, D., Evans, J. W., Yuan, P., Farmer, C. A., Oppenheimer, M., George, J. M., et al. (2020) · International Journal of Neuropsychopharmacology · doi:10.1093/ijnp/pyaa025 · Cited by 63 · cited 1×
“An additional small ( n = 19) phase II crossover of AV-101 in individuals with TRD was also negative ( p = 0.71, d = 0.22) [160].”
BackgroundInfluentialSelf-citationLeal, G. C., Souza-Marques, B., Mello, R. P., Bandeira, I. D., Caliman-Fontes, A. T., Carneiro, B. A., Faria-Guimarães, D., Guerreiro-Costa, L. N. F., Jesus-Nunes, A. P., Silva, S. S., et al. (2023) · Journal of Affective Disorders · doi:10.1016/j.jad.2023.02.151 · Cited by 62 · cited 1×
“[122].”
Murrough, J. W., Stade, E., Sayed, S., Ahle, G., Kiraly, D. D., Welch, A., Collins, K. A., Soleimani, L., Iosifescu, D. V., & Charney, D. S. (2017) · Journal of Affective Disorders · doi:10.1016/j.jad.2017.04.072 · Cited by 62 · cited 1×
“It exhibited high response rates without the emergence of suicidal ideation, dissociation, or psychotomimetic effects in an early phase II clinical trial with TRD patients [152].”
BackgroundDefinition of Treatment-Resistant Depression in the Medicare Population
Bradley N. Gaynes, M. D., Gary Asher, M. D., Gerald Gartlehner, M. D., Valerie Hoffman, P. D., Josh Green, B. A., Erin Boland, M. S. P. H., Linda Lux, M. P. A., Charlotte Randolph, B. A., Carla Bann, P. D., Emmanuel Cokker-Schwimmer, M. P. H., et al. (2018) · Systematic Review Data Repository · doi:10.26300/4j7h-jk02 · Cited by 58
Zorumski, C. F., Nagele, P., Mennerick, S., & Conway, C. R. (2015) · Frontiers in Psychiatry · doi:10.3389/fpsyt.2015.00172 · Cited by 57
Involvement of AMPA receptors in the antidepressant-like effects of dextromethorphan in mice
Nguyen, L., & Matsumoto, R. R. (2015) · Behavioural Brain Research · doi:10.1016/j.bbr.2015.03.024 · Cited by 51 · cited 2×
“The unconfirmed mechanism of AD action may rely on σ 1 (“opioid-like”) receptor activation, monoamin-ergic neurotransmitter reuptake inhibition, and nicotinic acetylcholine (nACh) receptor antagonism, leading to downstream AMPAR activation [147–149].”
BackgroundRoss, E. L., & Soeteman, D. I. (2020) · Psychiatric Services · doi:10.1176/appi.ps.201900625 · Cited by 51 · cited 1×
“Independent groups conducting cost-effectiveness analyses have consistently determined that esketamine/Spravato exceeds standard cost-effectiveness thresholds and is currently too expensive for widespread or long-term use in the United States [107,108].”
BackgroundEssential Medicinal Chemistry of Essential Medicines
Serafini, M., Cargnin, S., Massarotti, A., Pirali, T., & Genazzani, A. A. (2020) · Journal of Medicinal Chemistry · doi:10.1021/acs.jmedchem.0c00415 · Cited by 46 · cited 1×
“N 2 O is one of the World Health Organization’s essential medicines, and its clinical administration has been considered safe for more than 150 years [125].”
BackgroundRevisiting the Monoamine Hypothesis of Depression: A New Perspective
Goldberg, J. S., Bell, C. E., & Pollard, D. A. (2014) · Perspectives in Medicinal Chemistry · doi:10.4137/pmc.s11375 · Cited by 45 · cited 1×
“GABAergic deficits involve the concomitant presence of neurophysiological, neuroendocrine, cognitive, and behavioral findings [32,66,67], which may be reversed with targeted therapeutics.”
BackgroundNovel Pathways in the Treatment of Major Depression: Focus on the Glutamatergic System
Tomasetti, C., Montemitro, C., Fiengo, A. L. C., Santone, C., Orsolini, L., Valchera, A., Carano, A., Pompili, M., Serafini, G., Perna, G., et al. (2019) · Current Pharmaceutical Design · doi:10.2174/1381612825666190312102444 · Cited by 44 · cited 1×
“Overall, Treatment Resistant Depression (TRD) is associated with several comorbid features, including prolonged mental and physical dysfunction, increased healthcare spending, worse clinical outcomes, and a higher risk of suicide [4,6–9].”
BackgroundKetamine metabolite pilot study in a suicidal depression trial
Grunebaum, M. F., Galfalvy, H. C., Choo, T.-H., Parris, M. S., Burke, A. K., Suckow, R. F., Cooper, T. B., & Mann, J. J. (2019) · Journal of Psychiatric Research · doi:10.1016/j.jpsychires.2019.08.005 · Cited by 41 · cited 1×
“Despite repeated and robust demonstration of antidepressant effects across animal models with R,R-HNK, higher plasma levels appear to confer less improvement in clinical studies of depression and suicidal ideation [59,60].”
BackgroundDichtel, L. E., Nyer, M., Dording, C., Fisher, L. B., Cusin, C., Shapero, B. G., Pedrelli, P., Kimball, A. S., Rao, E. M., Mischoulon, D., et al. (2020) · The Journal of Clinical Psychiatry · doi:10.4088/jcp.19m12887 · Cited by 40 · cited 1×
“Ganaxolone is an additional ALLO-like compound that demonstrates AD efficacy in early phase II trials [186,187].”
BackgroundUmbricht, D., Niggli, M., Sanwald-Ducray, P., Deptula, D., Moore, R., Grünbauer, W., Boak, L., & Fontoura, P. (2020) · The Journal of Clinical Psychiatry · doi:10.4088/jcp.18m12470 · Cited by 39 · cited 1×
“Decoglurant (Roche), an mGlu2/3 antagonist receptor, was tested in a large clinical trial ( n = 370), where the primary objective was to access antidepressive and procongnitive of the compound versus placebo as an adjunctive therapy to SSRI/SNRI therapy in individuals with TRD [140].”
MethodYan, D., Liu, B., Wei, X., Ou, W., Liao, M., Ji, S., Peng, Y., Liu, J., Wu, S., Wang, M., et al. (2022) · Psychiatry Research · doi:10.1016/j.psychres.2022.114867 · Cited by 38
de Boer, J. N., Vingerhoets, C., Hirdes, M., McAlonan, G. M., Amelsvoort, T. V., & Zinkstok, J. R. (2019) · Psychiatry Research · doi:10.1016/j.psychres.2019.06.020 · Cited by 38 · cited 2×
“In TRD, AD efficacy was seen in early open-label studies but not replicated by more rigorous clinical trials [144,179], (see Table 1).”
BackgroundLee, S.-Y., Chen, S.-L., Chang, Y.-H., Chen, S.-H., Chu, C.-H., Huang, S.-Y., Tzeng, N.-S., Wang, C.-L., Lee, I. H., Yeh, T. L., et al. (2012) · Journal of Affective Disorders · doi:10.1016/j.jad.2012.01.024 · Cited by 35 · cited 1×
“A study group found negative results when combining dextromethorphan to valproic acid in order to improve depressive symptoms in patients with bipolar disorder [150].”
BackgroundChen, L., Chen, C., Chen, C., Chang, H., Huang, M., & Xu, K. (2020) · The American Journal on Addictions · doi:10.1111/ajad.12978 · Cited by 33 · cited 1×
“Data from recreational ketamine users show that long-term ketamine use can lead to renal and bladder toxicity, cognitive impairment, dependence, and induced suicidal ideation during withdrawal [101,102].”
BackgroundRapastinel - an investigational NMDA-R modulator for major depressive disorder: evidence to date
Ragguett, R.-M., Rong, C., Kratiuk, K., & McIntyre, R. S. (2019) · Expert Opinion on Investigational Drugs · doi:10.1080/13543784.2019.1559295 · Cited by 30 · cited 4×
“Based on safety and efficacy data obtained in phase I and II trials [164], rapastinel is not associated with ketamine-like dissociation and was granted fast track status and later breakthrough therapy designation for MDD in 2016 [161].”
BackgroundInfluentialZhong, H., Rong, J., Zhu, C., Liang, M., Li, Y., & Zhou, R. (2020) · International Journal of Neuropsychopharmacology · doi:10.1093/ijnp/pyaa020 · Cited by 28 · cited 1×
“GABAergic deficits involve the concomitant presence of neurophysiological, neuroendocrine, cognitive, and behavioral findings [32,66,67], which may be reversed with targeted therapeutics.”
BackgroundThe effect of methadone on depression among addicts: a systematic review and meta-analysis
Mohammadi, M., Kazeminia, M., Abdoli, N., Khaledipaveh, B., Shohaimi, S., Salari, N., & Hosseinian-Far, M. (2020) · Health and Quality of Life Outcomes · doi:10.1186/s12955-020-01599-3 · Cited by 28 · cited 1×
“Methadone itself has repeatedly demonstrated efficacy treating depression among opioid use disorder patients [130].”
BackgroundChen, X., Wang, M., Hu, Y., Zhan, Y., Zhou, Y., Zheng, W., Liu, W., Wang, C., Zhong, X., Li, H., et al. (2021) · European Archives of Psychiatry and Clinical Neuroscience · doi:10.1007/s00406-020-01221-z · Cited by 27 · cited 1×
“Improvements in working memory might be predictive of anti-suicidal responses in this population as well [87].”
BackgroundBrexanolone for postpartum depression
Hutcherson, T. C., Cieri-Hutcherson, N. E., & Gosciak, M. F. (2020) · American Journal of Health-System Pharmacy · doi:10.1093/ajhp/zxz333 · Cited by 25 · cited 2×
“However, a recent meta-analysis found less decisive conclusions [184].”
BackgroundResultAgboola, F., Atlas, S. J., Touchette, D. R., Fazioli, K., & Pearson, S. D. (2020) · Journal of Managed Care & Specialty Pharmacy · doi:10.18553/jmcp.2020.26.1.16 · Cited by 24 · cited 1×
“Independent groups conducting cost-effectiveness analyses have consistently determined that esketamine/Spravato exceeds standard cost-effectiveness thresholds and is currently too expensive for widespread or long-term use in the United States [107,108].”
BackgroundAllopregnanolone (1938–2019): A trajectory of 80 years of outstanding scientific achievements
Pinna, G. (2020) · Neurobiology of Stress · doi:10.1016/j.ynstr.2020.100246 · Cited by 24 · cited 2×
“ALLO’s therapeutic mechanism is mediated largely by its GABA A R modulation, but likely sustained via downstream GABA gene expression regulation and transcriptional changes [24,180].”
BackgroundWierońska, J. M., & Pilc, A. (2019) · Pharmacology & Therapeutics · doi:10.1016/j.pharmthera.2018.08.010 · Cited by 23 · cited 1×
“Receptors that are able to receive and process the signals from glutamate or GABA are present on all cells in the brain, including neurons and glia [13].”
BackgroundWatanabe, M., Marcy, B., Hiroki, A., Watase, H., Kinoshita, K., Iijima, M., Marumo, T., Zarate, C. A., & Chaki, S. (2022) · International Journal of Neuropsychopharmacology · doi:10.1093/ijnp/pyab062 · Cited by 22 · cited 1×
“TS-161 (Taisho Pharmaceutical) is also an mGlu2/3 antagonist receptor, like the previous compound on our review, but this one was only tested in a preclinical–clinical phase I trial [141].”
BackgroundPiva, A., Caffino, L., Mottarlini, F., Pintori, N., Castillo Díaz, F., Fumagalli, F., & Chiamulera, C. (2021) · Molecular Neurobiology · doi:10.1007/s12035-021-02352-7 · Cited by 21 · cited 1×
“This property may open a window during which delivery of secondary agents (or psychotherapy) can maximize and prolong beneficial adaptations [194,195].”
BackgroundLiu, H., Kerzner, J., Demchenko, I., Wijeysundera, D. N., Kennedy, S. H., Ladha, K. S., & Bhat, V. (2022) · Acta Psychiatrica Scandinavica · doi:10.1111/acps.13432 · Cited by 19 · cited 1×
“Several trials with N 2 O are currently enrolling for depression (MDD and bipolar), suicidal ideation, post-traumatic stress disorder, and others [129]. d-Methadone (dextromethadone/REL-1017) is the d-stereoisomer of methadone.”
BackgroundAre NMDA and opioid receptors involved in the antidepressant actions of ketamine?
Hashimoto, K. (2020) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.2001264117 · Cited by 19 · cited 1×
“Notably however, whereas glutamatergic neurotransmission appears critical to the therapeutic efficacy of these compounds, whether direct NMDAR antagonism is primarily responsible for the ultimate effects is very much unsettled [74].”
BackgroundDeuterated dextromethorphan/quinidine for agitation in Alzheimer's disease
Khoury, R. (2022) · Neural Regeneration Research · doi:10.4103/1673-5374.324842 · Cited by 16 · cited 1×
“Phase III results (TRIAD-1/2) for Alzheimer’s-related agitation have generated conflicting results per Avanir’s/Otsuka’s press releases; however, full publications are yet to be released [153].”
BackgroundGhaemi, N., Sverdlov, A., Shelton, R., & Litman, R. (2021) · European Psychiatry · doi:10.1192/j.eurpsy.2021.897 · Cited by 15
Olney, N. T., & Rosen, H. J. (2010) · PubMed · Cited by 13
Back to the Future: Esmethadone, the (Maybe) Nonopiate Opiate, and Depression
Nemeroff, C. B. (2022) · American Journal of Psychiatry · doi:10.1176/appi.ajp.2021.21121204 · Cited by 12 · cited 1×
“However, some have questioned whether it is truly free of abuse potential [133].”
BackgroundA spectroscopic approach toward depression diagnosis: local metabolism meets functional connectivity
Demenescu, L. R., Colic, L., Li, M., Safron, A., Biswal, B., Metzger, C. D., Li, S., & Walter, M. (2017) · European Archives of Psychiatry and Clinical Neuroscience · doi:10.1007/s00406-016-0726-1 · Cited by 11 · cited 1×
“Abnormalities in volume, activity, and connectivity in cortico-limbic networks have been consistently linked to depressive pathophysiology [14,15].”
BackgroundCosson, V., Schaedeli‐Stark, F., Arab‐Alameddine, M., Chavanne, C., Guerini, E., Derks, M., & Mallalieu, N. L. (2018) · Clinical and Translational Science · doi:10.1111/cts.12566 · Cited by 7 · cited 1×
“Pooled pharmacokinetic data from four phase I and one phase II studies also suggested that clearance was twofold higher in smokers and 40% higher in males [175].”
BackgroundAnnouncing the first novel class of rapid-onset antidepressants in clinical practice
Fasipe, O., Akhideno, P., Owhin, O., & Ibiyemi-Fasipe, O. (2019) · Journal of Medical Sciences · doi:10.4103/jmedsci.jmedsci_36_19 · Cited by 6 · cited 2×
“Apimostinel has been tested in two phase I studies and a larger phase II RDBPCT, showing rapid AD effects after a single, high-dose IV administration [165].”
BackgroundGutierrez-Esteinou, R., Maximos, B., Riesenberg, R., Johnson, K. A., Aimetti, A., Lappalainen, J., & Masuoka, L. (2019) · Biological Psychiatry · doi:10.1016/j.biopsych.2019.03.459 · Cited by 6 · cited 2×
“However, future studies should examine daily oral maintenance doses following a short-course IV lead in to bolster real-world efficacy and feasibility in a way that BRX cannot [187].”
BackgroundKetamine: From Abused Drug to Rapid-Acting Antidepressant
(2020) · doi:10.1007/978-981-15-2902-3 · Cited by 6 · cited 1×
“Data from recreational ketamine users show that long-term ketamine use can lead to renal and bladder toxicity, cognitive impairment, dependence, and induced suicidal ideation during withdrawal [101,102].”
BackgroundComments to Drs. Gastaldon, Raschi, Kane, Barbui, and Schoretsanitis
Doherty, T., Daly, E., Miller, J., Popova, V., Cepeda, M. S., Drevets, W. C., & Canuso, C. M. (2020) · Psychotherapy and Psychosomatics · doi:10.1159/000512311 · Cited by 5 · cited 1×
“Janssen-sponsored investigators have also weighed in on this issue [116].”
BackgroundJones, A., Streicher, C., Alter, S., Thomas, Z., & Tabuteau, H. (2023) · CNS Spectrums · doi:10.1017/s1092852923002080 · Cited by 5 · cited 1×
“This will be important to replicate in larger RCTs, as co-occurring anxiety is a significant risk factor for TRD [158].”
BackgroundGuidetti, C., Serra, G., Pani, L., Pappagallo, M., Maglio, G., Martin, S. D., Mattarei, A., Folli, F., Manfredi, P. L., & Fava, M. (2023) · The Primary Care Companion For CNS Disorders · doi:10.4088/pcc.22m03267 · Cited by 4 · cited 1×
“Results from a sub-analysis made from the phase II study accessing subjective cognitive measures from both MADRS and SDQ showed improvement in cognitive functions in the groups that received the drug compared to placebo in 14 days of evaluation [135].”
MethodMcGirr, A., Cole, J., Sohn, M., Harris, A., & Bray, S. (2022) · Biological Psychiatry · doi:10.1016/j.biopsych.2022.02.213 · Cited by 3 · cited 1×
“Significantly greater improvements were seen with adjunctive DCS compared to placebo (d = 0.96) [172].”
BackgroundInfluentialTreatment-refractory depression: Definitions and characteristics
Berman, R. M., Narasimhan, M., & Charney, D. S. (1997) · Depression and Anxiety · doi:10.1002/(sici)1520-6394(1997)5:4<154::aid-da2>3.0.co;2-d · cited 1×
“Well-established clinical correlates of TRD include persistent anhedonia and anxiety, the presence of one or more medical and/or psychiatric comorbidities, as well as duration and frequency of depressive episodes [10].”
Background
Research works printed but not linked: 2
- Sage Therapeutics (2023, September 04). Sage Therapeutics Reports Topline Results from Pivotal Phase 3 MOUNTAIN Study of SAGE-217 in Major Depressive Disorder. Available online: https://www.businesswire.com/news/home/20191205005375/en/4676027/Sage-Therapeutics-Reports-Topline-Results-from-Pivotal-Phase-3-MOUNTAIN-Study-of-SAGE-217-in-Major-Depressive-Disorder.
- Sage Therapeutics (2023, September 04). Business Wire. Sage Therapeutics and Biogen Announce FDA Accepts Filing of New Drug Application and Grants Priority Review of Zuranolone in the Treatment of Major Depressive Disorder and Postpartum Depression. Available online: https://www.businesswire.com/news/home/20230205005025/en/.
Cited by
From Synaptic Plasticity to Neurodegeneration: BDNF as a Transformative Target in Medicine
Toader, C., Șerban, M., Munteanu, O., Covache-Busuioc, R.-A., Enyedi, M., Ciurea, A. V., & Tătaru, C. P. (2025) · International Journal of Molecular Sciences · doi:10.3390/ijms26094271 · Cited by 184
Treatment-resistant depression: molecular mechanisms and management
Kajumba, M. M., Kakooza‐Mwesige, A., Nakasujja, N., Attix, D. K., & Canli, T. (2024) · Molecular Biomedicine · doi:10.1186/s43556-024-00205-y · Cited by 106
“The balance between the inhibitory GABAergic and excitatory glutamatergic neurotransmitter systems [25] is very essential in brain functioning since all neurons and glial cells have glutamate and GABA receptors [155].”
BackgroundFrom Stress to Synapse: The Neuronal Atrophy Pathway to Mood Dysregulation
Krasner, H., Ong, C. V., Hewitt, P., & Vida, T. A. (2025) · International Journal of Molecular Sciences · doi:10.3390/ijms26073219 · Cited by 42
“Increasing evidence suggests that TRD may be linked to excitatory and inhibitory neurotransmission disruptions, particularly glutamatergic overactivity and GABAergic deficits [52].”
Astrocytic GABAergic Regulation in Alcohol Use and Major Depressive Disorders
Ali, D. N., Ali, H. M., Lopez, M. R., Kang, S., & Choi, D. (2024) · Cells · doi:10.3390/cells13040318 · Cited by 30
“Brexanolone (SAGE-547) and zuranolone (SAGE-217) are investigational drugs that target GABA A Rs and have shown promise in clinical trials for postpartum depression [165] (Table 2).”
BackgroundChang, Z., Zhu, Y., Wang, P., Du, L., Wu, M., Wang, X., Kong, C., Huang, D., Xie, R., Guo, J., et al. (2025) · 中国科学通报:英文版 · doi:10.1016/j.scib.2025.04.010 · Cited by 20
Metadata
- Authors
- Vecera, C. M., C. Courtes, A., Jones, G., Soares, J. C., & Machado-Vieira, R.
- Affiliations
- The University of Texas Health Science Center at Houston (US)
- Department of Psychiatry and Behavioral Sciences, University of Texas Health Science Center, Houston, TX 77054, USA
- John S. Dunn Behavioral Sciences Center at UTHealth Houston, 5615 H.Mark Crosswell Jr St, Houston, TX 77021, USA
- Venue
- Pharmaceuticals
- Publisher
- MDPI AG
- Published
- 2023-11-07
- Volume
- 16
- Issue
- 11
- Pages
- 1572
- ISSN
- 1424-8247 (ISSN-L)
- PMC
- PMC10675154
- OpenAlex
- W4388453068
- Cited by
- 48
- References
- 179
- Citations by year
- 2026: 16 · 2025: 20 · 2024: 12
- FWCI
- 1.73
- Type
- journal article
- Language
- en
- Open access
- gold
- doi.org
- Licence
- Locations
- Pharmaceuticals (publishedVersion, cc-by)
- PubMed Central (publishedVersion, cc-by)
- PubMed (publishedVersion)
- Digital Commons-TMC (Texas Medical Center) (submittedVersion)
- DOAJ (DOAJ: Directory of Open Access Journals) (submittedVersion, cc-by-sa)
- Topics
- Health Sciences › Medicine › Pharmacology (medical) › Treatment of Major Depression
- Life Sciences › Neuroscience › Cellular and Molecular Neuroscience › Neuroscience and Neuropharmacology Research
- Health Sciences › Medicine › Psychiatry and Mental health › Electroconvulsive Therapy Studies
- Keywords
- treatment-resistant depression, major depressive disorder, NMDA receptor antagonism, ketamine, esketamine, D-cycloserine, GABA-A receptor modulation, brexanolone, postpartum depression, antidepressant mechanism, drug safety profile
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
The claim verdicts this report counts are experimental: their accuracy is not yet measured.
A language model drew the claims from the paper on 2026-10-05, under version 3 of the claim definition (model deepseek-v4.1-flash, prompt extract-v3).
A second model labelled each claim on 2026-10-05 (model jev-1.13-20260917, definition revision gold-guideline-v0.2).
Cited sources are checked with a language model’s help (qwen3.8-omni-flash and gpt-6-sol).
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.